Next Article in Journal
From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs
Previous Article in Journal
A Tutorial Review on the Fluorescent Probes as a Molecular Logic Circuit—Digital Comparator
Previous Article in Special Issue
Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (Danio rerio) Model: Involvement of Cholinergic System and Brain Oxidative Stress
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 17
10.3390/molecules28176328
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Marine Plasmalogens: A Gift from the Sea with Benefits for Age-Associated Diseases

by
Shinji Yamashita
1,
Taiki Miyazawa
2,
Ohki Higuchi
2,
Mikio Kinoshita
1 and
Teruo Miyazawa
2,*
1
Department of Life and Food Sciences, Obihiro University of Agriculture and Veterinary Medicine, Obihiro 080-8555, Japan
2
Food and Biotechnology Platform Promoting Project, New Industry Creation Hatchery Center (NICHe), Tohoku University, Sendai 980-8579, Japan
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(17), 6328; https://doi.org/10.3390/molecules28176328
Submission received: 28 June 2023 / Revised: 23 August 2023 / Accepted: 28 August 2023 / Published: 29 August 2023
(This article belongs to the Collection Neuroprotection Mediated by Natural Products and Their Chemical Derivatives)
Browse Figures
Review Reports Versions Notes

Abstract

:
Aging increases oxidative and inflammatory stress caused by a reduction in metabolism and clearance, thus leading to the development of age-associated diseases. The quality of our daily diet and exercise is important for the prevention of these diseases. Marine resources contain various valuable nutrients, and unique glycerophospholipid plasmalogens are found abundantly in some marine invertebrates, including ascidians. One of the major classes, the ethanolamine class (PlsEtn), exists in a high ratio to phospholipids in the brain and blood, while decreased levels have been reported in patients with age-associated diseases, including Alzheimer’s disease. Animal studies have shown that the administration of marine PlsEtn prepared from marine invertebrates improved PlsEtn levels in the body and alleviated inflammation. Animal and human studies have reported that marine PlsEtn ameliorates cognitive impairment. In this review, we highlight the biological significance, relationships with age-associated diseases, food functions, and healthcare materials of plasmalogens based on recent knowledge and discuss the contribution of marine plasmalogens to health maintenance in aging.

Graphical Abstract

1. Introduction

Aging decreases metabolic, clearance, and immune functions and increases oxidative and inflammatory stress [1,2]. For example, a decrease in the clearance of amyloid-β (Aβ) from the brain by aging is hypothesized to develop into Alzheimer’s disease (AD) via chronic oxidation and inflammation [3]. As human life expectancy is high in contemporary society, it is necessary to reduce the risk of age-associated diseases.
At the beginning of life, the sea is still mysterious, and marine resources possess various valuable nutrients that are not found in land resources. Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) as n-3 polyunsaturated fatty acids (PUFAs) contained in marine food contribute to health maintenance in current diets containing excessive n-6 PUFAs and saturated fatty acids [4]. Algae-derived xanthophylls, including fucoxanthin and astaxanthin, have been reported to exhibit not only antioxidative activity but also various food functions [5].
Plasmalogens are glycerophospholipids (GPLs) with a vinyl ether bond at the sn-1 position. In particular, the ethanolamine class (PlsEtn) is abundantly distributed in the nervous system, including the brain, and PlsEtn is thought to exhibit nerve protection as an endogenous antioxidant. In some marine invertebrates, high concentrations of PlsEtn exist in the muscles and viscera because of lower neural differentiation than that in vertebrates [6,7,8]. Reportedly, PlsEtn levels in the brain and blood are altered by aging and some age-associated diseases, including AD [9,10], and the administration of PlsEtn from marine invertebrates (marine PlsEtn) alleviates the impairments caused by aging [11,12]. In this review, we discuss and summarize the biological significance of plasmalogens and their relationship with age-associated diseases, food functions, and healthcare materials.

2. Structures and Roles of Plasmalogens

2.1. Structures and Distribution

GPLs are composed of a glycerol bone with two fatty chains and a polar head with phosphate. They are classified by their polar heads. For example, ethanolamine and choline GPLs (EtnGpl and ChoGpl), the major classes of GPLs found in the biological membranes of mammals, possess phosphoethanolamine and phosphocholine as their polar head, respectively. Moreover, GPLs are classified into three subclasses with alkyl, alkenyl, or acyl linkages at the sn-1 position of the glycerol moiety. In the case of EtnGpl, the subclasses are 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine (PakEtn), 1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine (PlsEtn), and 1,2-diacyl-sn-glycero-3-phosphoethanolamine (PtdEtn). In the case of ChoGpl, the subclasses are 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (PakCho), 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine (PlsCho), and phosphatidylcholine (PtdCho). The alkenylacyl form is called plasmalogen. Fatty alcohols at the sn-1 position of plasmalogens consist primarily of the C16:0 (palmitoyl), C18:0 (stearoyl), or C18:1 (oleoyl) carbon chains, whereas those at the sn-2 position consist primarily of PUFAs such as DHA and arachidonic acid (ARA).
In mammals, plasmalogens are ubiquitous in the body (Table 1 and Table 2). However, their ratio to phospholipids depends on the organ. The ratio of PlsEtn to EtnGpl is high in the nervous system, including the brain (50–90%; especially high ratio in the myelin sheath), heart (25–75%), blood plasma (approximately 50%), and red blood cells (RBCs; 45–65%), whereas it is low in the liver (<10%) [13,14,15]. The ratio of PlsCho to ChoGpl is basically lower than that of PlsEtn, with the highest being 5–40% in the heart. Tissues having high levels of plasmalogens (i.e., the brain and heart) indicate low expression of lyso-plasmalogenase, which hydrolyzes the vinyl ether bond of lyso-plasmalogens, while tissues having low levels, like the liver, exhibit high expression [16].

2.2. Biological Role

Plasmalogens play various roles in biological membranes. Plasmalogens are closer to the sn-1 and sn-2 chains than those in diacyl-types; therefore, plasmalogens strengthen lipid membranes and lower their fluidity, both of which are related to cellular functions [56,57]. Plasmalogens scavenge reactive oxygen species (ROS), such as singlet oxygen (1O2) and superoxide (O2−), at their alkenyl (vinyl ether) linkages [58,59]. Plasmalogens also store PUFAs at the sn-2 position, and the PUFAs are released by phospholipase A2 (PLA2), including the plasmalogen-selective PLA2 [60]. The released PUFAs can be metabolized into eicosanoids and docosanoids, which exhibit various bioactivities, including the promotion and inhibition of inflammation [61]. PLA2 isoforms differ in specificity depending on the linkage, length, and unsaturation of the carbon chains at the sn-1 and sn-2 positions; therefore, plasmalogens and PLA2 can control biological reactions [62].
Plasmalogens are synthesized in the peroxisomes and endoplasmic , and the initial reaction is an acylation of dihydroxyacetone phosphate (DHAP) by acyltransferase (DHAP-AT). Peroxisome biogenesis disorders, which are congenital dysfunctions of the peroxisome, impair the metabolism of lipids and ROS (e.g., low plasmalogen levels and promotion of inflammation), thus resulting in various symptoms, including hypomyelination. Zellweger syndrome and rhizomelic chondrodysplasia punctata (RCDP) are severe types of peroxisome biogenesis disorders, and most patients with their diseases die during infancy. Mutant cells deficient in plasmalogen synthesis exhibit low resistance to oxidation, and the addition of alkylglycerol as a plasmalogen precursor increases plasmalogen levels to enhance oxidative resistance [63]. Plasmalogen levels in cells are tightly administered; as feedback inhibition, excessive levels of plasmalogens reduce the levels of fatty acyl-CoA reductase 1 (Far1), which provides fatty alcohols in the synthesis, by promoting the degradation of the protein to control the plasmalogen levels [64]. Cells, mice, and humans deficient in peroxisomes have decreased PlsEtn levels but increased PtdEtn levels alternatively, and the total EtnGpl levels are maintained [65].
The significance of plasmalogens in the brain and nerves has been extensively investigated. Because PlsEtn easily forms an inverse hexagonal phase at body temperature compared with PtdEtn, PlsEtn is involved in membrane fusion during synaptic transmission [66]. In plasmalogen-deficient mice (knockout of the DHAP-AT gene), myelination in the spinal cord and optic nerves was improved by intraperitoneal (i.p.) injection of alkyl glycerol [67]. The knockdown of the DHAP-AT gene in the hippocampus of adult mice decreases memory function and neurogenesis [68]. According to a recent study, a decrease in PlsEtn levels reduces cholesterol synthesis; because the brain does not receive cholesterol from the blood, low PlsEtn levels in the brain lead to a shortage of 24-hydroxycholesterol as a cholesterol metabolite and a ligand of the liver X receptor (LXR), which inhibits myelin formation via LXR [64]. Additionally, plasmalogens are reported to be related to ferroptosis, a type of cell death caused by the accumulation of phospholipid hydroperoxides. Saturated fatty acids, which are metabolized to fatty alcohols by Far1, enhance the effects of ferroptosis inducers [69]. Because Far1 levels receive feedback inhibition by plasmalogens, such as those described above, a decrease in the brain levels of plasmalogens may induce neurocyte death.
In terms of the action of plasmalogens on the heart and blood, there are reports on their antioxidant properties [70,71,72]. In macrophages, which are derived from monocytes and are responsible for the immune response, PlsEtn affects the signal transduction of inflammation by providing ARA as a source of eicosanoids [73] and by controlling the number and size of lipid rafts [54]. Because plasmalogens in the heart and blood plasma possess the same levels of PlsCho as PlsEtn, whereas those in other organs are predominantly PlsEtn, PlsCho may play important roles in the heart and blood [74]. Mice deficient in mitochondrial transacylase tafazzin, a model of Barth syndrome, had decreased cardiac levels of PlsCho but not PlsEtn, whereas a significant decrease in PlsEtn levels was observed in the brain, kidney, and liver [45,75]. However, the biological significance of plasmalogens in the organs remains unclear.

3. Alterations of Plasmalogens in Aging and Associated Diseases

3.1. Aging

Aging is associated with cellular functional impairments, including mitochondrial dysfunction, that induce chronic oxidative and inflammatory stress [1,2]. For example, in human plasma and RBCs, the levels of GPL peroxides (PLOOHs), the first oxides of GPLs, increase depending on aging, and hyperlipidemia enhances the accumulation of PLOOHs with aging [76,77,78]. Reportedly, ChoGpl peroxides (PCOOHs) evoke monocyte adherence to the arterial wall during the initiation of atherosclerosis [79], and aged RBCs, which accumulate PLOOHs, reduce their ability to transport oxygen to the organs. Therefore, aging synergistically increases the risk of various diseases caused by oxidative and inflammatory stress.
In the human brain, plasmalogen levels peak in middle age and tend to decrease in old age [80,81], along with myelin (rich in PlsEtn) [82]. Free aldehydes and α-hydroxyaldehydes derived from the sn-1 position of plasmalogen oxides are markedly increased in the older adult human brain [81]. In human plasma and RBCs, plasmalogen levels decrease with aging [9]. This is because aging reduces peroxisomal functions [83] and promotes the degradation of the vinyl ether bond in plasmalogens by cytochrome c and oxidative stress [84]. A decrease in the levels of the antioxidant GPL plasmalogens reduces oxidative resistance and induces membrane dysfunction, including that of lipid rafts.

3.2. Alzheimer’s Disease

AD is the most common form of dementia worldwide. One of the pathological characteristics of AD is the progressive aggregation and accumulation of Aβ peptide in the senile plaques of the human brain. Because brain Aβ, particularly its fibril form, is highly neurotoxic, the progressive aggregation of Aβ is a critical step in AD pathogenesis [85]. Aging promotes chronic inflammation and Aβ accumulation, increasing the risk of developing and advancing AD [86,87].
Plasma Aβ is hypothesized to readily contact RBCs and impair their functions in the circulating human blood [88,89]. Our group and other researchers investigated this hypothesis and found that Aβ induces oxidative injury in RBCs by binding to them and causing the accumulation of PLOOHs [90,91]. Additionally, Aβ induces the binding of RBCs to endothelial cells and decreases endothelial viability, possibly by generating oxidative and inflammatory stress [92]. Moreover, RBC Aβ and PCOOH levels increase with age in healthy subjects, and RBC PCOOH levels increase in patients with AD [93,94].
By contrast, the levels of PlsEtn and PlsCho have been reported to decrease specifically in the brain and serum of patients with AD, depending on the severity of the disease [10,50,95,96]. We also analyzed the levels of Aβ, PCOOHs, and PlsEtn in the blood of patients with AD and their spouses (healthy subjects) (Figure 1) [97]. Evidently, plasma from patients with AD exhibited lower concentrations of PlsEtn species, particularly PlsEtn bearing a DHA moiety. Additionally, lower PlsEtn and higher PCOOH levels were observed in the RBCs of patients with AD. In both the AD and control blood samples, RBC PCOOH levels were correlated with plasma levels of Aβ40, particularly in patients with AD, and each PlsEtn species exhibited different correlations with plasma Aβ. Furthermore, PlsEtn bearing DHA suppressed the formation and disruption of Aβ fibrils in vitro, whereas the PtdEtn and PtdCho species were not affected (Figure 2) [97]. Together with the toxicities of Aβ fibrils [85,86,87,88,89,90,91,92], a decrease in PlsEtn levels is believed to weaken the blood and brain, thus advancing AD symptoms.

3.3. Parkinson’s Disease

Parkinson’s disease (PD) is characterized by motor dysfunction caused by the loss of dopaminergic neurons in the substantia nigra pars compacta and the depletion of dopamine in the nigrostriatal pathway. Aging increases PD morbidity, which is responsible for mitochondrial dysfunction and chronic oxidative and inflammatory stress [98]. Furthermore, in the advanced stages of PD, some patients develop dementia, and Aβ deposition, a pathological feature of AD, is observed in the brain [99]. In the PD brain, plasmalogens were lower than those in the control brain, but not significantly; however, in lipid rafts from the PD brain, the levels of plasmalogens were significantly lower [95,100]. Lipid rafts are strongly associated with signal transduction. It has been suggested that a reduction in plasmalogen levels decreases membrane strength and the levels of eicosanoids and docosanoids from PUFAs, which affect signal transduction. Additionally, PlsEtn levels in the plasma and RBCs of patients with PD are significantly lower than those in control subjects [101,102]. The lipid composition of blood is thought to reflect that of the organs [103]. In contrast, the reduction in blood PlsEtn rich in PUFAs may induce impairment of brain blood flow, which is associated with PD [104]. It would be interesting to determine whether, in patients with PD, blood PlsEtn levels fall earlier than those of brain lipid rafts.

3.4. Arteriosclerosis

Aging and obesity induce chronic inflammation and dysfunction of the lipid metabolism, leading to arteriosclerosis and cardiovascular disease [100]. The oxidized low-density lipoprotein (LDL) containing PCOOHs induces epidemic apoptosis [101,102] and promotes monocyte adherence to the arterial walls [79]. Plasma PCOOH levels increase during aging, particularly during hyperlipidemia [76]. By contrast, the addition of plasmalogens in vitro increased the oxidative stability of LDL, which is dependent on its content [71]. Patients with hyperlipidemia, particularly those with high levels of both triglycerides and cholesterol, exhibit lower serum plasmalogen levels than healthy subjects; serum plasmalogen levels are negatively correlated with serum triglyceride levels [103]. Patients with familial hypercholesterolemia indicate lower plasmalogen levels in plasma and LDL compared with healthy subjects; the supplementation of α-tocopherol as a lipophilic antioxidant increases their levels [32]. Serum levels of plasmalogens, particularly PlsCho bearing oleic acid, exhibit correlations with atherosclerosis-related factors (positive with protective functions and negative with promotion factors) [104,105]. Patients with coronary artery disease have lower levels of plasma PlsCho [106,107] and RBC PlsEtn [31]. Animal models of ischemia show a decrease in plasmalogen levels and an increase in lipid oxides, including α-hydroxyaldehyde as a plasmalogen oxide, in the heart and spinal cord [108,109,110]. Together with their antioxidant properties [70,71,72], it is thought that blood plasmalogen levels are easily influenced by oxidative stress and abnormal lipid metabolism, and a decrease in plasmalogen levels reduces resistance to their stress. Therefore, maintaining blood levels may be important for health of the circulatory system.

3.5. Cancer

Cancers are accentuated by DNA damage, apoptosis, dysregulation of cell homeostasis, and dedifferentiation [111], which are caused by chronic inflammation from aging as well as a dangerous lifestyle [1,112]. Reportedly, cancers alter the metabolism of GPLs, including plasmalogens [113]. Many studies have reported that higher levels of ether lipids (i.e., plasmalogens and alkyl-GPLs) are observed in cancer cells and tumors than in normal cells and tissues. This is due to the upregulation of biosynthesis enzymes of ether lipids in malignant cells and ether lipids’ contribution to the promotion of cancer progression via the generation of signaling lipids [114]. Hypoxia, which is a factor in cancer progression, increases plasmalogen levels in in vitro colon cancer cells by activating the re-acylation of lyso-plasmalogens, not plasmalogen synthesis [115]. Patients with gastric carcinoma show higher plasma levels of PlsEtn [116]. In contrast, some studies reported that cancers decreased plasmalogen levels, esophageal tumors decreased PlsEtn and other phospholipids [117], and patients with pancreatic cancer exhibited lower serum levels of PlsEtn than control subjects [118]. Lyso-PlsEtn and n-3 PUFAs, provided from PlsEtn by epidermal secretory PLA2 (sPLA2-IID), promote skin cancer hypergrowth and reduce antitumor immunity, respectively [119]. Additionally, ferroptosis, an attractive target for anticancer therapy [120], is associated with plasmalogens. Plasmalogens containing PUFAs accelerate ferroptosis via lipid peroxidation [121], while plasmalogens with non-PUFAs suppress ferroptosis enhanced by saturated fatty acids [69]. The gene expression of transmembrane protein 189 (TMEM189), which catalyzes the desaturation of PakEtn to PlsEtn, has been correlated with resistance to ferroptosis inducers in 654 cancer cell lines [69]. The administration of the plasmalogen precursor alkylglycerol decreased the growth, vascularization, and dissemination of Lewis lung carcinoma in a mouse model that used grafted tumors and reduced the plasmalogen content in the tumors [122].

4. Food Functions of Plasmalogens

4.1. Resources

Although the bovine brain is used as a resource for complex lipids, such as PlsEtn, its use has become difficult owing to outbreaks of bovine spongiform encephalopathy. Similarly, because eating the central nervous system of mammals poses anthropozoonotic risks, resources from different parts or different phyla are required.
Marine invertebrates, which exhibit lower neural differentiation than mammals, reportedly contain high levels of PlsEtn [6]. Accordingly, we investigated the contents of EtnGpl subclasses in marine invertebrates [7]. PlsEtn content in marine invertebrates varies widely (200–5000 nmol/g wet weight). The marine invertebrates examined, excluding prawns, squids, and octopuses, exhibited a high ratio of PlsEtn to EtnGpl in the muscle and viscera (65–98 mol%) (Figure 3). Sea anemones and starfish, which are not or are rarely used as food, had the highest content and ratio of PlsEtn (>2500 nmol/g wet weight, >95 mol%). The edible parts of ascidians, sea urchins, and shellfish have varying PlsEtn contents (200–4000 nmol/g wet weight) and a higher ratio of PlsEtn than mammalian brains (>65 mol%). PlsEtn from marine invertebrates is abundant in DHA and EPA at the sn-2 position; for example, the PlsEtn bearing DHA (18:0/22:6-PlsEtn) ratio of ascidian muscle and viscera is 9 mol% and 31 mol% of the total PlsEtn, respectively, whereas the ratio of land meat (leg muscle of beef, pig, and chicken) is <1 mol% (Figure 4) [8].
Chicken skin and large cervid meat (caribou and moose) have also been reported to have high levels of PlsEtn (1000 nmol and 5000 nmol/g wet weight, respectively; 75 mol% and 50 mol%, respectively), and the fatty acid composition of PlsEtn is predominantly ARA [123,124]. Bovine heart is often used as a PlsCho resource [125,126] and is also abundant in PakCho. Large cervid meat, beef, lamb, tuna, and scallops have been reported to contain high levels of PlsCho [124,127]. Some shellfish have high levels of serine-type plasmalogens, similar to those of PlsEtn [128]. Plasmalogens have not been found in plants and fungi, whereas those with unusual fatty chains and head groups have been found in anaerobic bacteria [129,130].

4.2. Alteration during Storage and Cooking

Alterations in the plasmalogen levels during storage and cooking have also been reported. GPLs in oysters are enzymatically hydrolyzed mainly to lyso-forms and free fatty acids during storage, depending on time and temperature, whereas PlsEtn hydrolysis is lower than that of other GPLs [131]. Similarly, plasmalogens in fish are lost during storage in a time- and temperature-dependent manner, and ethanolamine- and PUFA-type plasmalogen species can easily undergo degradation and oxidation [132]. During the postmortem aging (wet aging) of beef and venison, PlsEtn species are hardly hydrolyzed compared to PtdEtn bearing ARA [133]. Overall, GPLs in raw foods during storage and postmortem aging at low temperatures are altered by phospholipase hydrolysis (i.e., PLA2, PLC, and PLD) and oxidation. Plasmalogens hardly undergo enzymatic hydrolysis because of their substrate specificities, whereas PlsEtn with PUFAs is easily oxidized owing to its active methylene and amino groups compared to the species having saturated and monounsaturated fatty acids and PlsCho.
Among the cooking processes, boiling results in a lower loss of plasmalogens in beef compared with roasting and frying, which reduce plasmalogen levels depending on time and temperature [134]. The surface plasmalogen loss during frying was higher than the core loss, and the surface loss was reduced by butter coating. This indicates that, in roasting and frying processes, plasmalogens may be lost easily by dripping and oxidation. Additionally, it is thought that combinations with others affect plasmalogen conditions; for example, cooking and reducing sugar at the same time may modify EtnGpl, including PlsEtn, to Maillard reaction compounds (e.g., amadori-EtnGpl) [135].

4.3. Absorption and Metabolism

To utilize the dietary functions of plasmalogens effectively, their digestion, absorption, and metabolism must be understood. Because the vinyl ether bond at the sn-1 position of plasmalogen is acid-hydrolyzed, plasmalogen degradation by gastric acid is thought to occur; however, plasmalogens contained in diets are hardly degraded because of the buffering action of the diets [136,137]. In rats, ingested plasmalogens are absorbed into the lymph but not the portal vein [125]. PlsEtn is hydrolyzed to lyso-PlsEtn, which does not bear fatty acids at the sn-2 position, and is re-esterized after absorption; interestingly, PlsEtn, even though it hardly bears ARA like oyster- and ascidian-derived products, is preferentially re-esterized with ARA and partly base-converted to PlsCho during absorption, and structural changes occur in the intestinal mucosa [125,138,139]. Lyso-phosphatidylcholine acyltransferase 3, which plays a major role in incorporating ARA into phospholipids, is highly expressed in the intestine [140]. When PlsCho was administered, PlsCho levels in the lymph were four-fold higher than PlsEtn levels when PlsEtn was administered, and the absorbed PlsCho was slightly base-converted to PlsEtn [125]. After marine PlsEtn administration, the peak levels of PlsEtn containing PUFAs (i.e., DHA, EPA, and ARA) were almost the same in blood plasma and decreased early [138,139], suggesting that each level of PlsEtn with PUFAs in plasma is strictly controlled and rapidly transferred to the RBCs and organs [141]. By contrast, continuous diets containing bovine-brain-derived phospholipids (100 g of phospholipids/kg diets; 22 mol% plasmalogens in phospholipids) for 7 days increased the plasma and liver levels of plasmalogens but not RBCs [137].

4.4. Impact on Neurodegeneration

Some scientific studies have reported that the administration of plasmalogens improves cognitive deficits and lipid composition in rodent models and humans with neurodegenerative disorders, including AD. The administration of scallop-derived plasmalogens tends to improve cognitive function in patients with mild cognitive impairment (MCI), AD, and PD and increase PlsEtn levels in plasma and RBCs (Table 3) [11,142,143,144]. Ascidian-derived plasmalogens tended to improve memory function in subjects with MCI and mild forgetfulness [12,145]. Chicken-derived plasmalogens reportedly indicated similar tendencies in healthy subjects with mild forgetfulness [146,147]. As noted above, the administration of plasmalogens (0.5–100 mg/day) is expected to improve cognitive impairment. By contrast, the supplementation of DHA and EPA as n-3 PUFAs (0.2–2.0 g/day) is reported to attenuate the symptoms of MIC, mild AD, and PD [148]. Considering supplementation with other GPLs, 0.6–1.0 g/day of PtdCho and 0.3 g/day of phosphatidylserine are reported to improve the cognitive impairment associated with cerebrovascular disease and elderly memory impairment, respectively [149]. It is difficult to reference the advantages of marine plasmalogens for humans compared to those of other lipids because of the differences in dose, duration, evaluation, daily diet, and race of the subjects in the reports above.
In experiments using rodent models of AD, the oral administration of marine plasmalogens from ascidians, scallops, and sea cucumbers improves the cognitive function and biochemical characteristics of AD (Table 4). In aged mice, the oral administration of marine plasmalogens improves cognitive function and promotes neurogenesis [150]. Neuroinflammation induced by Aβ accumulation, lipopolysaccharides (LPSs), and a high-fat diet impairs peroxisome function, including DHAP-AT, and subsequently reduces PlsEtn levels [151,152]. A reduction in brain PlsEtn levels leads to suppression of neurogenesis by reducing the expression of the brain-derived neurotrophic factor (BDNF) [68] and the promotion of neuronal death by raising the expression of the p75 neurotrophin receptor (p75NTR) and protein kinase Cδ (PKCδ) [151,153]. p75NTR plays a critical role in the production of Aβ, neuronal death, neurite degeneration, and tau hyperphosphorylation; an increase in PKCδ expression is observed in human brains with AD, and the activation of PKCδ enhances toll-like receptor 4 (TLR4)-mediated pro-inflammatory signaling. In contrast, marine PlsEtn administration suppresses brain Aβ accumulation and tau hyperphosphorylation to attenuate neuroinflammation and apoptosis by restoring tropomyosin receptor kinase A/p75NTR signaling and attenuating PKCδ expression [151,153,154].
The oral and intraperitoneal administration of plasmalogens prepared from chicken breast muscle also attenuates inflammatory stress and enhances memory [68,152,155]. Although chicken-derived PlsEtn promotes BDNF expression by activating ERK and AKT signaling to induce neurogenesis in young mice, marine PlsEtn enhances memory function better [68]. This may be because marine PlsEtn is richer in DHA and EPA than the chicken derivative. Although EPA-rich PtdEtn also exhibits neuroprotective effects, these effects are weaker than those of marine PlsEtn [154].
The beneficial effects are thought to occur because the administration of plasmalogens maintains brain PlsEtn levels [68,155,156]. The levels of PlsEtn bearing DHA in the cerebral cortex correlate with working-memory-related learning ability in AD rats [156]. PlsEtn containing DHA exhibits stronger suppressive effects on neuronal inflammation, neuronal apoptosis, and Aβ aggregation in vitro than other PlsEtn species [97,157,158]. PlsEtn bearing DHA strongly reduces γ-secretase activity and reduces Aβ production in vitro [159]. Small-sized liposomes can deliver content to the brain through the blood–brain barrier [160], and intravenous injection of liposomes containing PlsEtn with DHA has been reported to increase its concentration in the prefrontal cortex and locomotor activity in normal rats [161].
The utilization of plasmalogen precursors and analogs has also been attempted to treat neurodegenerative disorders. These oral administrations improve the decreased content of dopamine-related substances in the brain and intestine and improve behavior in mouse models of PD and RCDP [162,163,164]. Their administration markedly increases PlsEtn levels in the serum or plasma but does not significantly increase brain levels. Because a slight but significant increase in brain PlsEtn levels was observed in an experiment using a labeled precursor [49], plasmalogens and/or precursors can pass through the blood–brain barrier, but in very small quantities [165]. In contrast to AD and aging, RCDP possesses plasmalogen synthesis defects, and PD does not markedly decrease brain PlsEtn levels [95,162]. Therefore, in PD and RCDP, plasmalogens may help patients recover from peripheral impairments and improve central function.
Hence, the ingestion of plasmalogens, particularly marine derivatives rich in DHA and EPA, is expected to attenuate the origin and development of cognitive impairments associated with aging. As described above, plasmalogen ingestion can rescue brain PlsEtn levels observed in AD models [155,156], and the mechanism suggests that the suppression of chronic inflammation in the entire body improves plasmalogen synthesis and degradation in the brain to increase plasmalogen levels rather than transfer from circulating plasmalogens.
Table 4. Effects of administration of plasmalogens on age-associated cognitive impairments in animal studies.
Table 4. Effects of administration of plasmalogens on age-associated cognitive impairments in animal studies.
Resource and CompositionAnimalAdministrationEffectsRefs.
Ascidian viscera
EtnGpl composition: 80.4 mol% PlsEtn
Fatty composition: 22.0 mol% DHA, 37.1 mol% EPA, 7.6 mol% ARA		Fourth-generation male Wister rats that ate a fish-oil-deficient diet
12 weeks old
Aβ40 (4.9–5.5 nmol) and AlCl3 (0.5 μg) infusion into the cerebral ventricle and learning ability check for 12 weeks		Oral gavage of 200 mg (260 μmol) EtnGpl/kg/day for 6 wks from 24 weeks oldLong-term memoryMolecules 28 06328 i001; short-term memoryMolecules 28 06328 i001
Plasma levels of 18:0/22:6-, 18:0:20:5-, and 18:0:20:4-PlsEtnMolecules 28 06328 i001; RBC and liver levels of 18:0/22:6- and 18:0:20:5-PlsEtnMolecules 28 06328 i001; cerebral cortex levels of 18:0/22:6-PlsEtnMolecules 28 06328 i001		[156]
Egg yolk
EtnGpl composition: 4.0 mol% PlsEtn
Fatty composition: 2.7 mol% DHA, 0.1 mol% EPA, 13.7 mol% ARA		Long-term memory⬌; short-term memory⬌
Plasma, RBC, liver, and cerebral cortex levels of PlsEtn species⬌
Sea cucumber
PlsEtn composition: 93.4% PlsEtn
Fatty acid composition: 45.6% EPA		Male SD rats
6 weeks old
Aβ42 (conc.: unclear) infusion into the cerebral ventricle		Oral gavage of 150 mg EtnGpl/kg/day for 26 daysMemoryMolecules 28 06328 i001Molecules 28 06328 i001
In hippocampus: Aβ accumulationMolecules 28 06328 i002; tau hyperphosphorylationMolecules 28 06328 i002Molecules 28 06328 i002; inflammationMolecules 28 06328 i002Molecules 28 06328 i002; apoptosisMolecules 28 06328 i002Molecules 28 06328 i002
In cortex: oxidative resistanceMolecules 28 06328 i001Molecules 28 06328 i001		[154]
Sea cucumber
(PtdEtn enzymatically prepared from PtdCho)
PtdEtn composition: 92.6% PtdEtn
Fatty acid composition: 49.3% EPA 		MemoryMolecules 28 06328 i001
In hippocampus: Aβ accumulationMolecules 28 06328 i002; tau hyperphosphorylationMolecules 28 06328 i002; inflammationMolecules 28 06328 i002; apoptosisMolecules 28 06328 i002
In cortex: oxidative resistanceMolecules 28 06328 i001
Scallop
Pls composition: unclear
Fatty acid composition: 28.7% DHA, 26.1% EPA, 10.2% ARA		Male C57/6J mice
6 months old
i.p. LPS (250 μg/kg/day) for 7 days at 9 months old		Drinking water containing 0.1 μg/mL for 3 monthsIn cortex: PKCδ-positive microglial cellsMolecules 28 06328 i002[153]
Male triple-transgenic mouse model of AD (PS1, tau, and APP)
3 months old		Drinking water containing 1 μg/mL for 15 monthsIn cortex: PKCδ-positive microglial cellsMolecules 28 06328 i002; PKCδ proteinMolecules 28 06328 i002
Sea cucumber
Pls composition: unclear		Male APP/PS1 mice
20 weeks old		A diet containing 0.1% PlsEtn for 16 weeksLong-term memoryMolecules 28 06328 i001; short-term memoryMolecules 28 06328 i001
In hippocampus: Aβ generationMolecules 28 06328 i002; soluble AβMolecules 28 06328 i002; insoluble AβMolecules 28 06328 i002; tau hyperphosphorylationMolecules 28 06328 i002; neurodegenerationMolecules 28 06328 i002; apoptosisMolecules 28 06328 i002; lipid accumulationMolecules 28 06328 i002; p75NTRMolecules 28 06328 i002; TrkA phosphorylationMolecules 28 06328 i001
In cortex: Aβ accumulationMolecules 28 06328 i002; apoptosisMolecules 28 06328 i002
In brain unclear part: oxidative resistanceMolecules 28 06328 i001
In liver: lipid accumulationMolecules 28 06328 i002; p75NTRMolecules 28 06328 i002		[151]
Sea cucumber
PlsEtn composition: 93.4% PlsEtn
Fatty acid composition: 11.4% DHA, 45.6% EPA, 10.1% ARA		Male SAMP8 mice
6 months old		A high-fat diet containing 1% PlsEtn for 2 monthsMemoryMolecules 28 06328 i001
In hippocampus: Aβ generationMolecules 28 06328 i002; soluble AβMolecules 28 06328 i002; insoluble Aβ40Molecules 28 06328 i002; insoluble Aβ42Molecules 28 06328 i001
In white matter: oxidative resistanceMolecules 28 06328 i001
In brain unclear part: tau hyperphosphorylationMolecules 28 06328 i002; glial activationMolecules 28 06328 i002; inflammationMolecules 28 06328 i002; apoptosisMolecules 28 06328 i002; ARA contentMolecules 28 06328 i001		[166]
Ascidian
Pls composition: unclear		Female C57BL/6J mice
16 months old		Oral gavage of 200 mg Pls/kg/day for 2 monthsMemoryMolecules 28 06328 i001
In hippocampus: synaptic conditions (number, form, genesis)Molecules 28 06328 i001; neurogenesisMolecules 28 06328 i001; glial activationMolecules 28 06328 i002; cytokine mRNA levelsMolecules 28 06328 i002		[150]
Chicken breast muscle
Pls composition: 96.5% PlsEtn, 2.5% PlsCho
Fatty acid composition: 23.8% DHA, 0.9% EPA, 21.9% ARA		Male C57BL/6 mice
8 weeks old		Diet containing 0.01% Pls for 6 weeksMemoryMolecules 28 06328 i001
In hippocampus: Pls levelMolecules 28 06328 i001; neurogenesisMolecules 28 06328 i001		[68]
Chicken breast muscle
Pls composition: 96.5% PlsEtn, 2.5% PlsCho
Fatty acid composition of PlsEtn: 23.8% DHA, 0.9% EPA, 21.9% ARA		Drinking water containing 0.01% Pls (w/v) for 6 weeksLong-term memory⬌; short-term memoryMolecules 28 06328 i001
Scallop
Pls composition: 96.5% PlsEtn, 2.5% PlsCho
Fatty acid composition of PlsEtn: 37.1% DHA, 27.8% EPA, 24.9% ARA		Long-term memoryMolecules 28 06328 i001; short-term memoryMolecules 28 06328 i001
Chicken breast muscle
Pls composition: unclear		Male C57/6J mice
7 months old
i.p. LPS (250 μg/kg/day) for 7 days at 10 months old		Drinking water containing 0.1 or 10 μg Pls/mL for 3 monthsMemoryMolecules 28 06328 i001
In cortex and hippocampus: Aβ accumulationMolecules 28 06328 i002; glial activationMolecules 28 06328 i002; cytokine mRNA levelsMolecules 28 06328 i002 		[152]
Chicken breast muscle
Pls composition: 47.6% PlsEtn (18.6% DHA, 24.9% ARA), 49.3% PlsCho (2.3% DHA, 17.2% ARA)		Male C57/6J mice
10 months old
i.p. LPS (250 μg/kg/day) for 7 days		i.p. 20 mg Pls/kg/day for 7 days along with LPS treatmentIn PFC and hippocampus: Aβ accumulationMolecules 28 06328 i002; glial activationMolecules 28 06328 i002; cytokine mRNA levelsMolecules 28 06328 i002; PlsEtn levelsMolecules 28 06328 i001[155]
Aβ, amyloid-β; AD, Alzheimer’s disease; ARA, arachidonic acid; DHA, docosaxaenoic acid; EPA, eicosapentaenoic acid; EtnGpl, ethanolamine glycerophospholipid; LPS, lipopolysaccharide; PFC, prefrontal cortex; PKCδ, protein kinase Cδ; Pls, plasmalogen; PlsCho, choline plasmalogen; PlsEtn, ethanolamine plasmalogen; p75NTR, p75 neurotrophin receptor; TrkA, tropomyosin receptor kinase A; Molecules 28 06328 i002, decrease; Molecules 28 06328 i001 increase; ⬌, no change.

4.5. Impact on Arteriosclerosis

Plasmalogen precursors and marine PlsEtn suppress the development of arteriosclerosis in rodent models. A plasmalogen precursor (butyl alcohol) suppressed the formation of atherosclerotic plaques in ApoE- or ApoE/glutathione peroxidase-1 (GPx1)-deficient mice fed a high-fat diet [72]. Additionally, precursor intake increases the plasma and cardiac levels of plasmalogens and lyso-phospholipids, which lose sn-1 fatty alcohols from plasmalogens by oxidation. In particular, in ApoE/GPx1-deficient mice, which possess lower resistance to oxidation, the precursor suppressed plasma levels of cholesterol and LDL and decreased oxidative stress and the expression of the vascular cellular adhesion molecule-1 in the aorta.
Sea-cucumber-derived PlsEtn intake attenuated the increase in plasma cholesterol and LDL levels to suppress the formation of atherosclerotic plaques in ApoE- or LDL-receptor-deficient mice fed a high-fat diet [167,168]. PlsEtn rich in EPA facilitated the synthesis and excretion of bile acids from excess cholesterol, whereas no effects were observed with the intake of EPA-rich PtdCho [167]. Likewise, in hamsters fed a high-fat diet, the administration of sea-urchin-derived PlsEtn and PakCho, which predominantly bear DHA and EPA, attenuated atherosclerotic lesions and hepatic steatosis by downregulating adipogenesis genes and upregulating lipid β-oxidation genes and bile acid biosynthesis genes in the liver; PlsEtn further increased hepatic sterol metabolism and serum levels of lipids bearing PUFAs compared to PakCho [169]. Additionally, dietary plasmalogens reduced hepatic cholesterol levels in rodents fed normal diets but not plasma cholesterol levels [137,170]. A decrease in the hepatic levels of PlsEtn and PlsCho bearing DHA and DHAP-AT expression was observed in a mouse model of nonalcoholic steatohepatitis (NASH), and cholesterol accumulation was induced in the livers of heterozygous DHAP-AT gene-deficient mice [171].
Overall, plasmalogens are responsible for the resistance to oxidation found in the vascular endothelium and hepatic sterol metabolism, and they act as antioxidants and LDL modulators in the vasculature to prevent arteriosclerosis. The structures of both the vinyl ether bond and EPA are important for suppressing arteriosclerosis.

4.6. Impact on Colon Impairments

The intestine digests food, absorbs nutrients and water, and is deeply implicated in the maintenance of human health via the immune and nervous systems [172]. However, intestinal impairments, such as colon cancer and inflammatory bowel disease (IBD), are becoming increasingly devastating diseases in all sexes worldwide, despite advances in diagnosis and treatment [173,174]. The incidence of IBD is increasing in younger generations and is thought to be caused by lifestyle factors, including diet, rather than aging. Aging and IBD increase the risk of developing colon cancer [175,176]. GPLs, particularly PtdCho, increase in colon cancer tumors by reducing their turnover [25]. Recently, PlsEtn metabolism was reported to be considerably dysregulated in dedifferentiated colon mucosa [177]. PlsCho has also been reported to inhibit cancer cell proliferation [178]. The authors indicated that plasmalogens might play a key role in protecting the normal colon mucosa from transitioning to hyper-proliferative and adenomatous polyps.
Marine plasmalogens suppress the formation of aberrant crypt foci (ACF) and intestinal inflammation in mouse models. A mouse model of ACF with precancerous colonic lesions was established via i.p. injection of 1,2-dimethylhydrazine (DMH). Diets containing ascidian-derived PlsEtn ameliorated DMH-induced ACF formation and oxidative and inflammatory stress in the colon [170]. A mouse model of IBD was established using drinking water containing sodium dextran sulfate (DSS). Dietary-ascidian-derived PlsEtn alleviated DSS-induced colon injury and neutrophil infiltration [179]. DMH and DSS treatments tended to decrease the PlsEtn species, particularly those bearing ARA, whereas ascidian-derived PlsEtn rescued their levels. In an in vitro intestinal tract model, ascidian-derived PlsEtn inhibited LPS-induced inflammation to protect intestinal cells [180]. Additionally, dietary PlsEtn improved cecal levels of short-chain fatty acids, which are metabolites of enteric bacteria and parameters of intestinal health and were decreased by DSS treatment [179]. Dietary PlsEtn rich in EPA altered enteric bacteria flora with a high-fat diet [168].
The in vivo and in vitro studies used fish oil and porcine-liver-derived PtdEtn for comparison. Marine PlsEtn performed better on intestinal inflammation caused by aging and other factors [170,179,180]. Therefore, the beneficial effects in the intestine are specific to PlsEtn bearing DHA and EPA.

5. Plasmalogens as Healthcare Materials

Among the materials used for the diagnosis, treatment, and management of human health and disease, plasmalogens have attractive functionalities as “healthcare materials”. In this section, the role of plasmalogens in the field of healthcare materials will be explained and examples of their use presented.

5.1. Materials for Functional Membrane of Biosensors

In recent years, “liquid biopsy” has gained attention as an important technique in the medical field for the early detection and diagnosis of biomarkers in the blood, including proteins, exosomes, small molecules, and circulating cells [181,182,183]. For the detection of biomarkers in liquid biopsy, low-cost and highly sensitive biosensors using semiconductor devices have been used. Such a biosensor adopts a functional membrane system that uses PtdCho. This system simulates the cell membrane and enables the evaluation of biomarkers in the blood and the assessment of compound permeability and adhesion to the cell membrane. Among these, the use of plasmalogens in functional membranes has garnered attention because it allows for the incorporation of detection sites such as antibodies, enzymes, and receptor molecules that cannot be incorporated with conventional PtdCho (Figure 5A) [184,185].

5.2. Materials for Light-Activated Liposomes

Bioactive compounds administered to the body via oral or intravenous administration achieve their activities after reaching the target organs or sites of inflammation. However, depending on the type of bioactive compound administered, its effectiveness may be limited because of instability or the body’s recognition of xenobiotic substances, raising concerns about the occurrence of unforeseen side effects [160]. One approach to solving such problems is to use a drug delivery system [186]. Drug delivery systems encapsulate bioactive components in formulated health materials such as liposomes and nanoparticles. This enhances therapeutic efficacy and reduces side effects. As introduced in Section 2 of this review, plasmalogens are characterized by the presence of an alkenyl (vinyl ether) linkage at the sn-1 position. Plasmalogens with this moiety have been reported to be characterized by their ability to alter membrane permeability in the process associated with the cleavage to lyso-phospholipids by photosensitized stimulation with laser light (Figure 5B) [187,188]. This mechanism allows the light-responsive release of bioactive compounds from plasmalogen-based liposomes. To date, the use of azobenzene to impart light sensitivity to liposomes has been limited in its clinical utility due to its high level of toxicity. On the other hand, plasmalogens exist in the body and have chemical structures that are more suitable and less toxic for healthcare use. Since ultraviolet and visible light reach only the superficial 1 cm layer of the skin but deeply into the eye, delivery studies targeting the retina are progressing using plasmalogen-based liposomes [189].

5.3. Materials for Nanoparticles with Endosomal Escape Capabilities

Depending on their size, surface structure, and charge, nanoparticles are taken up by cells via endocytosis and are subsequently degraded in the acidic environment of endosomes (pH < 6.5) [160,190]. The ability to escape from the endosome is essential for mRNA, drugs, bioactive substances, and other molecules to exert their effects in the cytoplasm. There are several ways to make nanoparticles achieve endosome escape, such as by using cationic amphiphiles, pH-sensitive polymers, and cell-penetrating peptides. During endocytosis, cationic amphiphiles attach and fuse with the anionic endosomal membrane, facilitating the release of bioactive compounds encapsulated in the nanoparticles into the cytoplasm (Figure 5C) [191]. Fay et al. reported that the transfection efficiency of mouse macrophage cell line (RAW 264.7) with plasmid DNA using polymeric nanoparticles modified with a cationic surfactant (dodecyltrimethylammonium bromide (DDAB)) was 1000 times higher compared to the commonly used lipofectamine [192]. Lipid nanoparticles can exhibit endosomal escape functionality by incorporating cationic lipids, such as plasmalogens [191,193]. Among the various available approaches, lipid nanoparticles are considered effective carriers for in vivo siRNA delivery [194]. Therefore, plasmalogens serve as valuable healthcare materials that provide endosomal escape functionality.

6. Conclusions

In this review, we discussed the beneficial effects of marine plasmalogens on aging-associated diseases, including cognitive impairment. Aging causes many metabolic impairments and increases oxidative and inflammatory stress, which decreases plasmalogen levels by suppressing biosynthesis and promoting degradation. A decrease in plasmalogen levels worsens aging-associated diseases via abnormal lipid signaling and reduced resistance to stress. The ingestion of marine plasmalogens, which are abundant in DHA and EPA, contributes to the maintenance or increase in plasmalogen levels in the body and intestines. Alterations in plasmalogen levels are due to exogenesis from ingested plasmalogens or endogenesis caused by reducing stress. Possessing the structures of both the vinyl ether bond and n-3 PUFAs is important for suppressing certain impairments. Plasmalogens possess chemical structures that are attractive for use as healthcare materials. We believe that the chronic administration of marine plasmalogens lowers the risk of age-associated diseases and has a unique capacity to profoundly improve quality of life.

Author Contributions

Conceptualization, S.Y. and T.M. (Taiki Miyazawa); writing—original draft preparation, S.Y.; writing—review and editing, T.M. (Taiki Miyazawa) and O.H.; supervision, M.K. and T.M. (Teruo Miyazawa). All authors have read and agreed to the published version of the manuscript.

Funding

Part of this research was supported by a grant from the Project of the NARO Bio-oriented Technology Research Advancement Institution (R&D Matching Funds in the Field for Knowledge Integration and Innovation) and JSPS KAKENHI Grant Number JP19K05892.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Not applicable.

References

  1. Shaw, A.C.; Goldstein, D.R.; Montgomery, R.R. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 2013, 13, 875–887. [Google Scholar] [CrossRef] [PubMed]
  2. Franceschi, C.; Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, S4–S9. [Google Scholar] [CrossRef] [PubMed]
  3. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356. [Google Scholar] [CrossRef]
  4. Calder, P.C.; Grimble, R.F. Polyunsaturated fatty acids, inflammation and immunity. Eur. J. Clin. Nutr. 2002, 56, S14–S19. [Google Scholar] [CrossRef]
  5. Patel, A.K.; Albarico, F.; Perumal, P.K.; Vadrale, A.P.; Nian, C.T.; Chau, H.T.B.; Anwar, C.; Wani, H.; Pal, A.; Saini, R.; et al. Algae as an emerging source of bioactive pigments. Bioresour. Technol. 2022, 351, 126910. [Google Scholar] [CrossRef]
  6. Yamashita, S.; Honjo, A.; Aruga, M.; Nakagawa, K.; Miyazawa, T. Preparation of marine plasmalogen and selective identification of molecular species by LC-MS/MS. J. Oleo Sci. 2014, 63, 423–430. [Google Scholar] [CrossRef]
  7. Yamashita, S.; Abe, A.; Nakagawa, K.; Kinoshita, M.; Miyazawa, T. Separation and detection of plasmalogen in marine invertebrates by high-performance liquid chromatography with evaporative light-scattering detection. Lipids 2014, 49, 1261–1273. [Google Scholar] [CrossRef]
  8. Yamashita, S.; Kanno, S.; Honjo, A.; Otoki, Y.; Nakagawa, K.; Kinoshita, M.; Miyazawa, T. Analysis of Plasmalogen Species in Foodstuffs. Lipids 2016, 51, 199–210. [Google Scholar] [CrossRef]
  9. Brosche, T. Plasmalogen phospholipids—Facts and theses to their antioxidative qualities. Arch. Gerontol. Geriatr. 1997, 25, 73–81. [Google Scholar] [CrossRef]
  10. Han, X.; Holtzman, D.M.; McKeel, D.W., Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 2001, 77, 1168–1180. [Google Scholar] [CrossRef]
  11. Fujino, T.; Yamada, T.; Asada, T.; Tsuboi, Y.; Wakana, C.; Mawatari, S.; Kono, S. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. EBioMedicine 2017, 17, 199–205. [Google Scholar] [CrossRef] [PubMed]
  12. Yamamoto, A.; Aizawa, T.; Kubomura, D.; Akahori, Y.; Yamashita, S.; Nakagawa, K.; Miyazawa, T. Effects of Ascidian-Derived Ethanolamine Plasmalogen on Cognitive Function and Its Safety -A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study-. Pharmacometrics 2023, 104, 17–24. [Google Scholar]
  13. Mawatari, S.; Katafuchi, T.; Miake, K.; Fujino, T. Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats. Lipids Health Dis. 2012, 11, 161. [Google Scholar] [CrossRef] [PubMed]
  14. Braverman, N.E.; Moser, A.B. Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta 2012, 1822, 1442–1452. [Google Scholar] [CrossRef] [PubMed]
  15. Bozelli, J.C., Jr.; Azher, S.; Epand, R.M. Plasmalogens and Chronic Inflammatory Diseases. Front. Physiol. 2021, 12, 730829. [Google Scholar] [CrossRef]
  16. Wu, L.C.; Pfeiffer, D.R.; Calhoon, E.A.; Madiai, F.; Marcucci, G.; Liu, S.; Jurkowitz, M.S. Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen. J. Biol. Chem. 2011, 286, 24916–24930. [Google Scholar] [CrossRef]
  17. Panganamala, R.V.; Horrocks, L.A.; Geer, J.C.; Cornwell, D.G. Positions of double bonds in the monounsaturated alk-1-enyl groups from the plasmalogens of human heart and brain. Chem. Phys. Lipids 1971, 6, 97–102. [Google Scholar] [CrossRef]
  18. Heymans, H.S.; Schutgens, R.B.; Tan, R.; van den Bosch, H.; Borst, P. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature 1983, 306, 69–70. [Google Scholar] [CrossRef]
  19. Guan, Z.; Grünler, J.; Piao, S.; Sindelar, P.J. Separation and Quantitation of Phospholipids and Their Ether Analogues by High-Performance Liquid Chromatography. Anal. Biochem. 2001, 297, 137–143. [Google Scholar] [CrossRef]
  20. O’Brien, J.S.; Sampson, E.L. Lipid composition of the normal human brain: Gray matter, white matter, and myelin. J. Lipid Res. 1965, 6, 537–544. [Google Scholar] [CrossRef]
  21. Seikagaku Data Book Editorial Board. Seikagaku Data Book I; The Japanese Biochemical Society, Ed.; Tokyo Kagaku Dojin: Tokyo, Japan, 1979. [Google Scholar]
  22. Rapport, M.M.; Lerner, B. The structure of plasmalogens IV. Lipids in normal and neoplastic tissues of man and in normal tissues of rabbit and rat. Biochim. Biophys. Acta 1959, 33, 319–325. [Google Scholar] [CrossRef] [PubMed]
  23. Hughes, B.P.; Frais, F.F. Changes in Plasmalogen Content of Human Heart and Skeletal Muscle with Age and Development. Nature 1967, 215, 993–994. [Google Scholar] [CrossRef] [PubMed]
  24. Takamura, H.; Kasai, H.; Arita, H.; Kito, M. Phospholipid molecular species in human umbilical artery and vein endothelial cells. J. Lipid Res. 1990, 31, 709–717. [Google Scholar] [CrossRef] [PubMed]
  25. Dueck, D.A.; Chan, M.; Tran, K.; Wong, J.T.; Jay, F.T.; Littman, C.; Stimpson, R.; Choy, P.C. The modulation of choline phosphoglyceride metabolism in human colon cancer. Mol. Cell Biochem. 1996, 162, 97–103. [Google Scholar] [CrossRef]
  26. Deeley, J.M.; Thomas, M.C.; Truscott, R.J.W.; Mitchell, T.W.; Blanksby, S.J. Identification of Abundant Alkyl Ether Glycerophospholipids in the Human Lens by Tandem Mass Spectrometry Techniques. Anal. Chem. 2009, 81, 1920–1930. [Google Scholar] [CrossRef]
  27. Chabot, M.C.; Greene, D.G.; Brockschmidt, J.K.; Capizzi, R.L.; Wykle, R.L. Ether-linked phosphoglyceride content of human leukemia cells. Cancer Res. 1990, 50, 7174–7178. [Google Scholar]
  28. Ojima-Uchiyama, A.; Masuzawa, Y.; Sugiura, T.; Waku, K.; Saito, H.; Yui, Y.; Tomioka, H. Phospholipid analysis of human eosinophils: High levels of alkylacylglycerophosphocholine (PAF precursor). Lipids 1988, 23, 815–817. [Google Scholar] [CrossRef]
  29. Farquhar, J.W.; Ahrens, E.H., Jr. Effects of dietary fats on human erythrocyte fatty acid patterns. J. Clin. Investig. 1963, 42, 675–685. [Google Scholar] [CrossRef]
  30. Engelmann, B.; Streich, S.; Schonthier, U.M.; Richter, W.O.; Duhm, J. Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochim. Biophys. Acta 1992, 1165, 32–37. [Google Scholar] [CrossRef]
  31. Mawatari, S.; Fukata, M.; Arita, T.; Maruyama, T.; Kono, S.; Fujino, T. Decreases of ethanolamine plasmalogen and phosphatidylcholine in erythrocyte are a common phenomenon in Alzheimer’s, Parkinson’s, and coronary artery diseases. Brain Res. Bull. 2022, 189, 5–10. [Google Scholar] [CrossRef]
  32. Brautigam, C.; Engelmann, B.; Reiss, D.; Reinhardt, U.; Thiery, J.; Richter, W.O.; Brosche, T. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis 1996, 119, 77–88. [Google Scholar] [CrossRef] [PubMed]
  33. Maeba, R.; Maeda, T.; Kinoshita, M.; Takao, K.; Takenaka, H.; Kusano, J.; Yoshimura, N.; Takeoka, Y.; Yasuda, D.; Okazaki, T.; et al. Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with aging. J. Atheroscler. Thromb. 2007, 14, 12–18. [Google Scholar] [CrossRef] [PubMed]
  34. Ikuta, A.; Sakurai, T.; Nishimukai, M.; Takahashi, Y.; Nagasaka, A.; Hui, S.P.; Hara, H.; Chiba, H. Composition of plasmalogens in serum lipoproteins from patients with non-alcoholic steatohepatitis and their susceptibility to oxidation. Clin. Chim. Acta 2019, 493, 1–7. [Google Scholar] [CrossRef] [PubMed]
  35. Takamura, H.; Tanaka, K.; Matsuura, T.; Kito, M. Ether phospholipid molecular species in human platelets. J. Biochem. 1989, 105, 168–172. [Google Scholar] [CrossRef]
  36. Wallner, S.; Orso, E.; Grandl, M.; Konovalova, T.; Liebisch, G.; Schmitz, G. Phosphatidylcholine and phosphatidylethanolamine plasmalogens in lipid loaded human macrophages. PLoS ONE 2018, 13, e0205706. [Google Scholar] [CrossRef]
  37. Poulos, A.; White, I.G. The phospholipid composition of human spermatozoa and seminal plasma. J. Reprod. Fertil. 1973, 35, 265–272. [Google Scholar] [CrossRef]
  38. Hoffman-Kuczynski, B.; Reo, N.V. Administration of myo-inositol plus ethanolamine elevates phosphatidylethanolamine plasmalogen in the rat cerebellum. Neurochem. Res. 2005, 30, 47–60. [Google Scholar] [CrossRef]
  39. Breckenridge, W.C.; Morgan, I.G.; Zanetta, J.P.; Vincendon, G. Adult rat brain synaptic vesicles. II. Lipid composition. Biochim. Biophys. Acta 1973, 320, 681–686. [Google Scholar] [CrossRef]
  40. Novák, F.; Tvrzická, E.; Hamplová, B.; Kolář, F.; Nováková, O. Postnatal development of phospholipids and their fatty acid profile in rat heart. Mol. Cell Biochem. 2006, 293, 23–33. [Google Scholar] [CrossRef]
  41. Post, J.A.; Verkleij, A.J.; Roelofsen, B.; de Kamp, J.A.F.O. Plasmalogen content and distribution in the sarcolemma of cultured neonatal rat myocytes. FEBS Lett. 1988, 240, 78–82. [Google Scholar] [CrossRef]
  42. Blank, M.L.; Cress, E.A.; Smith, Z.L.; Snyder, F. Dietary supplementation with ether-linked lipids and tissue lipid composition. Lipids 1991, 26, 166–169. [Google Scholar] [CrossRef]
  43. Vance, J.E. Lipoproteins secreted by cultured rat hepatocytes contain the antioxidant 1-alk-1-enyl-2-acylglycerophosphoethanolamine. Biochim. Biophys. Acta 1990, 1045, 128–134. [Google Scholar] [CrossRef] [PubMed]
  44. Surinlert, P.; Asuvapongpatana, S.; Srakaew, N.; Daungchinda, T.; Setou, M.; Weerachatyanukul, W. Changes of fatty acids in phosphatidylcholine on sperm membrane during Macrobrachium rosenbergii sperm transit through spermatic duct and lipid analysis in spermatic vesicles. Aquaculture 2016, 456, 62–69. [Google Scholar] [CrossRef]
  45. Kimura, T.; Kimura, A.K.; Ren, M.; Berno, B.; Xu, Y.; Schlame, M.; Epand, R.M. Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency. Biochemistry 2018, 57, 2162–2175. [Google Scholar] [CrossRef] [PubMed]
  46. Gross, R.W. Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum. Biochemistry 1985, 24, 1662–1668. [Google Scholar] [CrossRef]
  47. Sugiura, T.; Nakajima, M.; Sekiguchi, N.; Nakagawa, Y.; Waku, K. Different fatty chain compositions of alkenylacyl, alkylacyl and diacyl phospholipids in rabbit alveolar macrophages: High amounts of arachidonic acid in ether phospholipids. Lipids 1983, 18, 125–129. [Google Scholar]
  48. Amunugama, K.; Jellinek, M.J.; Kilroy, M.P.; Albert, C.J.; Rasi, V.; Hoft, D.F.; Shashaty, M.G.S.; Meyer, N.J.; Ford, D.A. Identification of novel neutrophil very long chain plasmalogen molecular species and their myeloperoxidase mediated oxidation products in human sepsis. Redox Biol. 2021, 48, 102208. [Google Scholar] [CrossRef] [PubMed]
  49. Wood, P.L.; Khan, M.A.; Smith, T.; Ehrmantraut, G.; Jin, W.; Cui, W.; Braverman, N.E.; Goodenowe, D.B. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis. 2011, 10, 182. [Google Scholar] [CrossRef]
  50. Goodenowe, D.B.; Cook, L.L.; Liu, J.; Lu, Y.; Jayasinghe, D.A.; Ahiahonu, P.W.; Heath, D.; Yamazaki, Y.; Flax, J.; Krenitsky, K.F.; et al. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer’s disease and dementia. J. Lipid Res. 2007, 48, 2485–2498. [Google Scholar] [CrossRef]
  51. Vecchini, A.; Del Rosso, F.; Binaglia, L.; Dhalla, N.S.; Panagia, V. Molecular defects in sarcolemmal glycerophospholipid subclasses in diabetic cardiomyopathy. J. Mol. Cell Cardiol. 2000, 32, 1061–1074. [Google Scholar] [CrossRef] [PubMed]
  52. Bizeau, J.B.; Albouery, M.; Gregoire, S.; Buteau, B.; Martine, L.; Crepin, M.; Bron, A.M.; Berdeaux, O.; Acar, N.; Chassaing, B.; et al. Dietary Inulin Supplementation Affects Specific Plasmalogen Species in the Brain. Nutrients 2022, 14, 3097. [Google Scholar] [CrossRef] [PubMed]
  53. Azad, A.K.; Sheikh, A.M.; Haque, A.; Osago, H.; Sakai, H.; Shibly, A.Z.; Yano, S.; Michikawa, M.; Hossain, S.; Tabassum, S.; et al. Time-Dependent Analysis of Plasmalogens in the Hippocampus of an Alzheimer’s Disease Mouse Model: A Role of Ethanolamine Plasmalogen. Brain Sci. 2021, 11, 1603. [Google Scholar] [CrossRef] [PubMed]
  54. Rubio, J.M.; Astudillo, A.M.; Casas, J.; Balboa, M.A.; Balsinde, J. Regulation of Phagocytosis in Macrophages by Membrane Ethanolamine Plasmalogens. Front. Immunol. 2018, 9, 1723. [Google Scholar] [CrossRef]
  55. Portilla, D.; Creer, M.H. Plasmalogen phospholipid hydrolysis during hypoxic injury of rabbit proximal tubules. Kidney Int. 1995, 47, 1087–1094. [Google Scholar] [CrossRef]
  56. Koivuniemi, A. The biophysical properties of plasmalogens originating from their unique molecular architecture. FEBS Lett. 2017, 591, 2700–2713. [Google Scholar]
  57. West, A.; Zoni, V.; Teague, W.E., Jr.; Leonard, A.N.; Vanni, S.; Gawrisch, K.; Tristram-Nagle, S.; Sachs, J.N.; Klauda, J.B. How Do Ethanolamine Plasmalogens Contribute to Order and Structure of Neurological Membranes? J. Phys. Chem. B 2020, 124, 828–839. [Google Scholar] [CrossRef]
  58. Maeba, R.; Yusufu, Y.; Shimasaki, H.; Ueta, N. Comparison of the oxidizability of various glycerophospholipids in bilayers by the oxygen uptake method. Lipids 2002, 37, 893–900. [Google Scholar] [CrossRef]
  59. Broniec, A.; Klosinski, R.; Pawlak, A.; Wrona-Krol, M.; Thompson, D.; Sarna, T. Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems. Free Radic. Biol. Med. 2011, 50, 892–898. [Google Scholar] [CrossRef]
  60. Farooqui, A.A.; Horrocks, L.A. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J. Mol. Neurosci. 2001, 16, 263–272; discussion 279–284. [Google Scholar] [CrossRef]
  61. Christie, W.W.; Harwood, J.L. Oxidation of polyunsaturated fatty acids to produce lipid mediators. Essays Biochem. 2020, 64, 401–421. [Google Scholar]
  62. Hayashi, D.; Mouchlis, V.D.; Dennis, E.A. Each phospholipase A(2) type exhibits distinct selectivity toward sn-1 ester, alkyl ether, and vinyl ether phospholipids. Biochim. Biophys. Acta 2022, 1867, 159067. [Google Scholar] [CrossRef] [PubMed]
  63. Zoeller, R.A.; Morand, O.H.; Raetz, C.R. A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem. 1988, 263, 11590–11596. [Google Scholar]
  64. Honsho, M.; Fujiki, Y. Regulation of plasmalogen biosynthesis in mammalian cells and tissues. Brain Res. Bull. 2023, 194, 118–123. [Google Scholar] [CrossRef] [PubMed]
  65. Dorninger, F.; Brodde, A.; Braverman, N.E.; Moser, A.B.; Just, W.W.; Forss-Petter, S.; Brügger, B.; Berger, J. Homeostasis of phospholipids—The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens. Biochim. Biophys. Acta 2015, 1851, 117–128. [Google Scholar] [CrossRef] [PubMed]
  66. Glaser, P.E.; Gross, R.W. Plasmenylethanolamine facilitates rapid membrane fusion: A stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry 1994, 33, 5805–5812. [Google Scholar] [CrossRef]
  67. Malheiro, A.R.; Correia, B.; Ferreira da Silva, T.; Bessa-Neto, D.; Van Veldhoven, P.P.; Brites, P. Leukodystrophy caused by plasmalogen deficiency rescued by glyceryl 1-myristyl ether treatment. Brain Pathol. 2019, 29, 622–639. [Google Scholar] [CrossRef]
  68. Hossain, M.S.; Mawatari, S.; Fujino, T. Plasmalogens, the Vinyl Ether-Linked Glycerophospholipids, Enhance Learning and Memory by Regulating Brain-Derived Neurotrophic Factor. Front. Cell Dev. Biol. 2022, 10, 828282. [Google Scholar]
  69. Cui, W.; Liu, D.; Gu, W.; Chu, B. Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis. Cell Death Differ. 2021, 28, 2536–2551. [Google Scholar] [CrossRef]
  70. Zoeller, R.A.; Grazia, T.J.; LaCamera, P.; Park, J.; Gaposchkin, D.P.; Farber, H.W. Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am. J. Physiol.-Heart Circ. Physiol. 2002, 283, H671–H679. [Google Scholar] [CrossRef]
  71. Hahnel, D.; Thiery, J.; Brosche, T.; Engelmann, B. Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arter. Thromb. Vasc. Biol. 1999, 19, 2431–2438. [Google Scholar] [CrossRef]
  72. Rasmiena, A.A.; Barlow, C.K.; Stefanovic, N.; Huynh, K.; Tan, R.; Sharma, A.; Tull, D.; de Haan, J.B.; Meikle, P.J. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice. Atherosclerosis 2015, 243, 598–608. [Google Scholar] [CrossRef] [PubMed]
  73. Gil-de-Gómez, L.; Astudillo, A.M.; Lebrero, P.; Balboa, M.A.; Balsinde, J. Essential Role for Ethanolamine Plasmalogen Hydrolysis in Bacterial Lipopolysaccharide Priming of Macrophages for Enhanced Arachidonic Acid Release. Front. Immunol. 2017, 8, 1251. [Google Scholar] [CrossRef] [PubMed]
  74. Maeba, R. Strange Phospholipids—Plasmalogen. Oleoscience 2005, 5, 405–415. [Google Scholar] [CrossRef]
  75. Kimura, T.; Kimura, A.K.; Ren, M.; Monteiro, V.; Xu, Y.; Berno, B.; Schlame, M.; Epand, R.M. Plasmalogen loss caused by remodeling deficiency in mitochondria. Life Sci. Alliance 2019, 2, e201900348. [Google Scholar] [CrossRef]
  76. Kinoshita, M.; Oikawa, S.; Hayasaka, K.; Sekikawa, A.; Nagashima, T.; Toyota, T.; Miyazawa, T. Age-related increases in plasma phosphatidylcholine hydroperoxide concentrations in control subjects and patients with hyperlipidemia. Clin. Chem. 2000, 46, 822–828. [Google Scholar] [CrossRef]
  77. Miyazawa, T.; Suzuki, T.; Fujimoto, K.; Kinoshita, M. Age-related change of phosphatidylcholine hydroperoxide and phosphatidylethanolamine hydroperoxide levels in normal human red blood cells. Mech. Ageing Dev. 1996, 86, 145–150. [Google Scholar] [CrossRef]
  78. Miyazawa, T. Lipid hydroperoxides in nutrition, health, and diseases. Proc. Jpn. Acad. Ser. B 2021, 97, 161–196. [Google Scholar] [CrossRef]
  79. Asai, A.; Okajima, F.; Nakagawa, K.; Ibusuki, D.; Tanimura, K.; Nakajima, Y.; Nagao, M.; Sudo, M.; Harada, T.; Miyazawa, T.; et al. Phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to intracellular adhesion molecule-1. J. Lipid Res. 2009, 50, 957–965. [Google Scholar] [CrossRef] [PubMed]
  80. Rouser, G.; Yamamoto, A. Curvilinear regression course of human brain lipid composition changes with age. Lipids 1968, 3, 284–287. [Google Scholar] [CrossRef]
  81. Weisser, M.; Vieth, M.; Stolte, M.; Riederer, P.; Pfeuffer, R.; Leblhuber, F.; Spiteller, G. Dramatic increase of alpha-hydroxyaldehydes derived from plasmalogens in the aged human brain. Chem. Phys. Lipids 1997, 90, 135–142. [Google Scholar] [CrossRef]
  82. Bartzokis, G. Alzheimer’s disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2011, 32, 1341–1371. [Google Scholar] [CrossRef] [PubMed]
  83. Terlecky, S.R.; Koepke, J.I.; Walton, P.A. Peroxisomes and aging. Biochim. Biophys. Acta 2006, 1763, 1749–1754. [Google Scholar] [CrossRef] [PubMed]
  84. Jenkins, C.M.; Yang, K.; Liu, G.; Moon, S.H.; Dilthey, B.G.; Gross, R.W. Cytochrome c is an oxidative stress-activated plasmalogenase that cleaves plasmenylcholine and plasmenylethanolamine at the sn-1 vinyl ether linkage. J. Biol. Chem. 2018, 293, 8693–8709. [Google Scholar] [CrossRef] [PubMed]
  85. Jack, C.R., Jr.; Knopman, D.S.; Jagust, W.J.; Shaw, L.M.; Aisen, P.S.; Weiner, M.W.; Petersen, R.C.; Trojanowski, J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010, 9, 119–128. [Google Scholar] [CrossRef] [PubMed]
  86. Newcombe, E.A.; Camats-Perna, J.; Silva, M.L.; Valmas, N.; Huat, T.J.; Medeiros, R. Inflammation: The link between comorbidities, genetics, and Alzheimer’s disease. J. Neuroinflamm. 2018, 15, 276. [Google Scholar] [CrossRef] [PubMed]
  87. Gibbs, D.; Barker, T. 2020 Alzheimer’s disease facts and figures. In Alzheimers Dement; Cambridge University Press: Cambridge, UK, 2020. [Google Scholar]
  88. Mattson, M.P.; Begley, J.G.; Mark, R.J.; Furukawa, K. Abeta25-35 induces rapid lysis of red blood cells: Contrast with Abeta1-42 and examination of underlying mechanisms. Brain Res. 1997, 771, 147–153. [Google Scholar] [CrossRef] [PubMed]
  89. Mohanty, J.G.; Eckley, D.M.; Williamson, J.D.; Launer, L.J.; Rifkind, J.M. Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer’s disease? Adv. Exp. Med. Biol. 2008, 614, 29–35. [Google Scholar]
  90. Jayakumar, R.; Kusiak, J.W.; Chrest, F.J.; Demehin, A.A.; Murali, J.; Wersto, R.P.; Nagababu, E.; Ravi, L.; Rifkind, J.M. Red cell perturbations by amyloid beta-protein. Biochim. Biophys. Acta 2003, 1622, 20–28. [Google Scholar] [CrossRef]
  91. Nakagawa, K.; Kiko, T.; Miyazawa, T.; Sookwong, P.; Tsuduki, T.; Satoh, A.; Miyazawa, T. Amyloid beta-induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett. 2011, 585, 1249–1254. [Google Scholar] [CrossRef]
  92. Nakagawa, K.; Kiko, T.; Kuriwada, S.; Miyazawa, T.; Kimura, F.; Miyazawa, T. Amyloid beta induces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci. Biotechnol. Biochem. 2011, 75, 2030–2033. [Google Scholar] [CrossRef]
  93. Kiko, T.; Nakagawa, K.; Tsuduki, T.; Suzuki, T.; Arai, H.; Miyazawa, T. Significance of lutein in red blood cells of Alzheimer’s disease patients. J. Alzheimers Dis. 2012, 28, 593–600. [Google Scholar] [CrossRef] [PubMed]
  94. Kiko, T.; Nakagawa, K.; Satoh, A.; Tsuduki, T.; Furukawa, K.; Arai, H.; Miyazawa, T. Amyloid beta levels in human red blood cells. PLoS ONE 2012, 7, e49620. [Google Scholar] [CrossRef] [PubMed]
  95. Ginsberg, L.; Rafique, S.; Xuereb, J.H.; Rapoport, S.I.; Gershfeld, N.L. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res. 1995, 698, 223–226. [Google Scholar] [CrossRef] [PubMed]
  96. Igarashi, M.; Ma, K.; Gao, F.; Kim, H.-W.; Rapoport, S.I.; Rao, J.S. Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex. J. Alzheimers Dis. 2011, 24, 507–517. [Google Scholar] [CrossRef]
  97. Yamashita, S.; Kiko, T.; Fujiwara, H.; Hashimoto, M.; Nakagawa, K.; Kinoshita, M.; Furukawa, K.; Arai, H.; Miyazawa, T. Alterations in the Levels of Amyloid-beta, Phospholipid Hydroperoxide, and Plasmalogen in the Blood of Patients with Alzheimer’s Disease: Possible Interactions between Amyloid-beta and These Lipids. J. Alzheimers Dis. 2016, 50, 527–537. [Google Scholar] [CrossRef]
  98. Trist, B.G.; Hare, D.J.; Double, K.L. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell 2019, 18, e13031. [Google Scholar] [CrossRef]
  99. Lim, E.W.; Aarsland, D.; Ffytche, D.; Taddei, R.N.; van Wamelen, D.J.; Wan, Y.M.; Tan, E.K.; Ray Chaudhuri, K.; Kings Parcog groupMDS Nonmotor Study Group. Amyloid-beta and Parkinson’s disease. J. Neurol. 2019, 266, 2605–2619. [Google Scholar] [CrossRef]
  100. Ferrucci, L.; Fabbri, E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 2018, 15, 505–522. [Google Scholar] [CrossRef]
  101. Kinoshita, M.; Shimokado, K. Autocrine FGF-2 is responsible for the cell density-dependent susceptibility to apoptosis of HUVEC: A role of a calpain inhibitor-sensitive mechanism. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2323–2329. [Google Scholar] [CrossRef]
  102. Harada-Shiba, M.; Kinoshita, M.; Kamido, H.; Shimokado, K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J. Biol. Chem. 1998, 273, 9681–9687. [Google Scholar] [CrossRef]
  103. Brosche, T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values. Arch. Gerontol. Geriatr. 2001, 32, 283–294. [Google Scholar] [CrossRef]
  104. Nishimukai, M.; Maeba, R.; Yamazaki, Y.; Nezu, T.; Sakurai, T.; Takahashi, Y.; Hui, S.P.; Chiba, H.; Okazaki, T.; Hara, H. Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state. J. Lipid Res. 2014, 55, 956–965. [Google Scholar] [CrossRef] [PubMed]
  105. Nishimukai, M.; Maeba, R.; Ikuta, A.; Asakawa, N.; Kamiya, K.; Yamada, S.; Yokota, T.; Sakakibara, M.; Tsutsui, H.; Sakurai, T.; et al. Serum choline plasmalogens-those with oleic acid in sn-2-are biomarkers for coronary artery disease. Clin. Chim. Acta 2014, 437, 147–154. [Google Scholar] [CrossRef] [PubMed]
  106. Meikle, P.J.; Wong, G.; Tsorotes, D.; Barlow, C.K.; Weir, J.M.; Christopher, M.J.; MacIntosh, G.L.; Goudey, B.; Stern, L.; Kowalczyk, A.; et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 2723–2732. [Google Scholar] [CrossRef] [PubMed]
  107. Sutter, I.; Klingenberg, R.; Othman, A.; Rohrer, L.; Landmesser, U.; Heg, D.; Rodondi, N.; Mach, F.; Windecker, S.; Matter, C.M.; et al. Decreased phosphatidylcholine plasmalogens—A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. Atherosclerosis 2016, 246, 130–140. [Google Scholar] [CrossRef]
  108. Dudda, A.; Spiteller, G.; Kobelt, F. Lipid oxidation products in ischemic porcine heart tissue. Chem. Phys. Lipids 1996, 82, 39–51. [Google Scholar] [CrossRef]
  109. Lukacova, N.; Halat, G.; Chavko, M.; Marsala, J. Ischemia-reperfusion injury in the spinal cord of rabbits strongly enhances lipid peroxidation and modifies phospholipid profiles. Neurochem. Res. 1996, 21, 869–873. [Google Scholar] [CrossRef]
  110. Lukacova, N.; Marsala, M.; Halat, G.; Marsala, J. Neuroprotective effect of graded postischemic reoxygenation in spinal cord ischemia in the rabbit. Brain Res. Bull. 1997, 43, 457–465. [Google Scholar] [CrossRef]
  111. Bartsch, H.; Nair, J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: Role of lipid peroxidation, DNA damage, and repair. Langenbeck’s Arch. Surg. 2006, 391, 499–510. [Google Scholar] [CrossRef]
  112. Matsuno, Y.; Atsumi, Y.; Shimizu, A.; Katayama, K.; Fujimori, H.; Hyodo, M.; Minakawa, Y.; Nakatsu, Y.; Kaneko, S.; Hamamoto, R.; et al. Replication stress triggers microsatellite destabilization and hypermutation leading to clonal expansion in vitro. Nat. Commun. 2019, 10, 3925. [Google Scholar] [CrossRef]
  113. Messias, M.C.F.; Mecatti, G.C.; Priolli, D.G.; de Oliveira Carvalho, P. Plasmalogen lipids: Functional mechanism and their involvement in gastrointestinal cancer. Lipids Health Dis. 2018, 17, 41. [Google Scholar] [CrossRef] [PubMed]
  114. Dahabieh, M.S.; Di Pietro, E.; Jangal, M.; Goncalves, C.; Witcher, M.; Braverman, N.E.; del Rincón, S.V. Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. Biochim. Biophys. Acta (BBA)—Rev. Cancer 2018, 1870, 103–121. [Google Scholar] [CrossRef] [PubMed]
  115. Tamiya-Koizumi, K.; Otoki, Y.; Nakagawa, K.; Kannagi, R.; Mizutani, N.; Suzuki, M.; Kyogashima, M.; Iwaki, S.; Aoyama, M.; Murate, T.; et al. Cellular concentrations of plasmalogen species containing a polyunsaturated fatty acid significantly increase under hypoxia in human colorectal cancer, Caco2 cells. Biochem. Biophys. Res. Commun. 2022, 611, 1–7. [Google Scholar] [CrossRef] [PubMed]
  116. Lv, J.; Lv, C.-Q.; Xu, L.; Yang, H. Plasma Content Variation and Correlation of Plasmalogen and GIS, TC, and TPL in Gastric Carcinoma Patients: A Comparative Study. Med. Sci. Monit. Basic. Res. 2015, 21, 157–160. [Google Scholar]
  117. Merchant, T.E.; de Graaf, P.W.; Minsky, B.D.; Obertop, H.; Glonek, T. Esophageal cancer phospholipid characterization by31P NMR. NMR Biomed. 1993, 6, 187–193. [Google Scholar] [CrossRef]
  118. Ritchie, S.A.; Akita, H.; Takemasa, I.; Eguchi, H.; Pastural, E.; Nagano, H.; Monden, M.; Doki, Y.; Mori, M.; Jin, W.; et al. Metabolic system alterations in pancreatic cancer patient serum: Potential for early detection. BMC Cancer 2013, 13, 416. [Google Scholar] [CrossRef]
  119. Murakami, M.; Miki, Y.; Sato, H.; Murase, R.; Taketomi, Y.; Yamamoto, K. Group IID, IIE, IIF and III secreted phospholipase A2s. Biochim. Biophys. Acta (BBA)—Mol. Cell Biol. Lipids 2019, 1864, 803–818. [Google Scholar] [CrossRef]
  120. Abe, C.; Miyazawa, T.; Miyazawa, T. Current Use of Fenton Reaction in Drugs and Food. Molecules 2022, 27, 5451. [Google Scholar] [CrossRef]
  121. Zou, Y.; Henry, W.S.; Ricq, E.L.; Graham, E.T.; Phadnis, V.V.; Maretich, P.; Paradkar, S.; Boehnke, N.; Deik, A.A.; Reinhardt, F.; et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 2020, 585, 603–608. [Google Scholar] [CrossRef]
  122. Pedrono, F.; Martin, B.; Leduc, C.; Le Lan, J.; Saiag, B.; Legrand, P.; Moulinoux, J.-P.; Legrand, A.B. Natural Alkylglycerols Restrain Growth and Metastasis of Grafted Tumors in Mice. Nutr. Cancer 2004, 48, 64–69. [Google Scholar] [CrossRef]
  123. Miake, K.; Yunoki, K.; Kawamura, J.; Fuchu, H.; Sugiyama, M.; Ohnishi, M. The Plasmalogen composition of post laying-eggs hen and the production method for edible use. Jpn. J. Zootech. Sci. 2014, 85, 153–161. [Google Scholar]
  124. Pham, T.H.; Manful, C.F.; Pumphrey, R.P.; Hamilton, M.C.; Adigun, O.A.; Vidal, N.P.; Thomas, R.H. Big game cervid meat as a potential good source of plasmalogens for functional foods. J. Food Compos. Anal. 2021, 96, 103724. [Google Scholar] [CrossRef]
  125. Nishimukai, M.; Yamashita, M.; Watanabe, Y.; Yamazaki, Y.; Nezu, T.; Maeba, R.; Hara, H. Lymphatic absorption of choline plasmalogen is much higher than that of ethanolamine plasmalogen in rats. Eur. J. Nutr. 2011, 50, 427–436. [Google Scholar] [CrossRef]
  126. Otoki, Y.; Kato, S.; Nakagawa, K.; Harvey, D.J.; Jin, L.-W.; Dugger, B.N.; Taha, A.Y. Lipidomic Analysis of Postmortem Prefrontal Cortex Phospholipids Reveals Changes in Choline Plasmalogen Containing Docosahexaenoic Acid and Stearic Acid Between Cases With and Without Alzheimer’s Disease. Neuromolecular Med. 2021, 23, 161–175. [Google Scholar] [CrossRef] [PubMed]
  127. Wu, Y.; Chen, Z.; Jia, J.; Chiba, H.; Hui, S.-P. Quantitative and Comparative Investigation of Plasmalogen Species in Daily Foodstuffs. Foods 2021, 10, 124. [Google Scholar] [CrossRef] [PubMed]
  128. Wang, J.; Liao, J.; Wang, H.; Zhu, X.; Li, L.; Lu, W.; Song, G.; Shen, Q. Quantitative and comparative study of plasmalogen molecular species in six edible shellfishes by hydrophilic interaction chromatography mass spectrometry. Food Chem. 2021, 334, 127558. [Google Scholar] [CrossRef] [PubMed]
  129. Řezanka, T.; Křesinová, Z.; Kolouchová, I.; Sigler, K. Lipidomic analysis of bacterial plasmalogens. Folia Microbiol. 2012, 57, 463–472. [Google Scholar] [CrossRef]
  130. Sato, N.; Kanehama, A.; Kashiwagi, A.; Yamada, M.; Nishimukai, M. Lymphatic Absorption of Microbial Plasmalogens in Rats. Front. Cell Dev. Biol. 2022, 10, 836186. [Google Scholar] [CrossRef]
  131. Chen, Q.; Wang, X.; Cong, P.; Liu, Y.; Wang, Y.; Xu, J.; Xue, C. Mechanism of Phospholipid Hydrolysis for Oyster Crassostrea plicatula Phospholipids During Storage Using Shotgun Lipidomics. Lipids 2017, 52, 1045–1058. [Google Scholar] [CrossRef]
  132. Chen, Z.; Jia, J.; Wu, Y.; Chiba, H.; Hui, S.-P. LC/MS analysis of storage-induced plasmalogen loss in ready-to-eat fish. Food Chem. 2022, 383, 132320. [Google Scholar] [CrossRef]
  133. Yamashita, S.; Shimada, K.; Sakurai, R.; Yasuda, N.; Oikawa, N.; Kamiyoshihara, R.; Otoki, Y.; Nakagawa, K.; Miyazawa, T.; Kinoshita, M. Decrease in Intramuscular Levels of Phosphatidylethanolamine Bearing Arachidonic Acid During Postmortem Aging Depends on Meat Cuts and Breed. Eur. J. Lipid Sci. Technol. 2019, 121, 1800370. [Google Scholar] [CrossRef]
  134. Wu, Y.; Chen, Z.; Chiba, H.; Hui, S.-P. Plasmalogen fingerprint alteration and content reduction in beef during boiling, roasting, and frying. Food Chem. 2020, 322, 126764. [Google Scholar] [CrossRef] [PubMed]
  135. Miyazawa, T.; Ibusuki, D.; Yamashita, S.; Nakagawa, K. Analysis of Amadori-glycated Phosphatidylethanolamine in the Plasma of Healthy Subjects and Diabetic Patients by Liquid Chromatography-Tandem Mass Spectrometry. Ann. N. Y. Acad. Sci. 2008, 1126, 291–294. [Google Scholar] [CrossRef]
  136. Hara, H.; Wakisaka, T.; Aoyama, Y. Lymphatic absorption of plasmalogen in rats. Br. J. Nutr. 2003, 90, 29–32. [Google Scholar] [CrossRef] [PubMed]
  137. Nishimukai, M.; Wakisaka, T.; Hara, H. Ingestion of plasmalogen markedly increased plasmalogen levels of blood plasma in rats. Lipids 2003, 38, 1227–1235. [Google Scholar] [CrossRef]
  138. Takahashi, T.; Kamiyoshihara, R.; Otoki, Y.; Ito, J.; Kato, S.; Suzuki, T.; Yamashita, S.; Eitsuka, T.; Ikeda, I.; Nakagawa, K. Structural changes of ethanolamine plasmalogen during intestinal absorption. Food Funct. 2020, 11, 8068–8076. [Google Scholar] [CrossRef]
  139. Yamashita, S.; Fujiwara, K.; Tominaga, Y.; Nguma, E.; Takahashi, T.; Otoki, Y.; Yamamoto, A.; Higuchi, O.; Nakagawa, K.; Kinoshita, M.; et al. Absorption Kinetics of Ethanolamine Plasmalogen and Its Hydrolysate in Mice. J. Oleo Sci. 2021, 70, 263–273. [Google Scholar] [CrossRef]
  140. Hashidate-Yoshida, T.; Harayama, T.; Hishikawa, D.; Morimoto, R.; Hamano, F.; Tokuoka, S.M.; Eto, M.; Tamura-Nakano, M.; Yanobu-Takanashi, R.; Mukumoto, Y.; et al. Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport. eLife 2015, 4, e06328. [Google Scholar] [CrossRef]
  141. Engelmann, B.; Bräutigam, C.; Kulschar, R.; Duhm, J.; Prenner, E.; Hermetter, A.; Richter, W.O.; Thiery, J.; Seidel, D. Reversible reduction of phospholipid bound arachidonic acid after low density lipoprotein apheresis. Evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into the red blood cell membrane. Biochim. Biophys. Acta 1994, 1196, 154–164. [Google Scholar] [CrossRef]
  142. Mawatari, S.; Ohara, S.; Taniwaki, Y.; Tsuboi, Y.; Maruyama, T.; Fujino, T. Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report. Park. Dis. 2020, 2020, 2671070. [Google Scholar] [CrossRef]
  143. Fujino, T.; Yamada, T.; Asada, T.; Ichimaru, M.; Tsuboi, Y.; Wakana, C.; Mawatari, S. Effects of Plasmalogen on Patients with Mild Cognitive Impairment: A Randomized, Placebo-Controlled Trial in Japan. J. Alzheimers Dis. Park. 2018, 8, 419. [Google Scholar] [CrossRef]
  144. Fujino, T.; Yamada, T.; Mawatari, S.; Shinfuku, N.; Tsuboi, Y.; Wakana, C.; Kono, S. Effects of Plasmalogen on Patients with Moderate-to-Severe Alzheimer’s Disease and Blood Plasmalogen Changes: A Multi-Center, Open-Label Study. J. Alzheimers Dis. Park. 2019, 9, 474. [Google Scholar]
  145. Watanabe, H.; Okawara, M.; Matahira, Y.; Mano, T.; Wada, T.; Suzuki, N.; Takara, T. The Impact of Ascidian (Halocynthia roretzi)-derived Plasmalogen on Cognitive Function in Healthy Humans: A Randomized, Double-blind, Placebo-controlled Trial. J. Oleo Sci. 2020, 69, 1597–1607. [Google Scholar] [CrossRef] [PubMed]
  146. Kotoura, S.; Yuasa, K.; Koikeda, T. Effects of Dietary Plasmalogens on Brain Function in the Healthy Subjects—Randomized Double-blind Placebo-controlled Parallel Group Comparison. Jpn. Pharmacol. Ther. 2017, 45, 1511–1521. [Google Scholar]
  147. Kawamura, J.; Kotoura, S.; Ando, T.; Kawasaki, Y.; Ebihara, S. The Evaluation Test of Brain Function by Oral Consumption of the Food Which Contain Plasmalogen—Randomized, Placebo-controlled, Double-blind Parallel-group Study. Jpn. Pharmacol. Ther. 2019, 47, 739–749. [Google Scholar]
  148. Janssen, C.I.F.; Kiliaan, A.J. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration. Prog. Lipid Res. 2014, 53, 1–17. [Google Scholar] [CrossRef]
  149. Olivera-Pueyo, J.; Pelegrin-Valero, C. Dietary supplements for cognitive impairment. Actas Esp. Psiquiatr. 2017, 45, 37–47. [Google Scholar]
  150. Gu, J.; Chen, L.; Sun, R.; Wang, J.-L.; Wang, J.; Lin, Y.; Lei, S.; Zhang, Y.; Lv, D.; Jiang, F.; et al. Plasmalogens Eliminate Aging-Associated Synaptic Defects and Microglia-Mediated Neuroinflammation in Mice. Front. Mol. Biosci. 2022, 9, 815320. [Google Scholar] [CrossRef]
  151. Liu, Y.; Cong, P.; Zhang, T.; Wang, R.; Wang, X.; Liu, J.; Wang, X.; Xu, J.; Wang, Y.; Wang, J.; et al. Plasmalogen attenuates the development of hepatic steatosis and cognitive deficit through mechanism involving p75NTR inhibition. Redox Biol. 2021, 43, 102002. [Google Scholar] [CrossRef]
  152. Hossain, M.S.; Tajima, A.; Kotoura, S.; Katafuchi, T. Oral ingestion of plasmalogens can attenuate the LPS-induced memory loss and microglial activation. Biochem. Biophys. Res. Commun. 2018, 496, 1033–1039. [Google Scholar] [CrossRef]
  153. Sejimo, S.; Hossain, M.S.; Akashi, K. Scallop-derived plasmalogens attenuate the activation of PKCδ associated with the brain inflammation. Biochem. Biophys. Res. Commun. 2018, 503, 837–842. [Google Scholar] [CrossRef]
  154. Che, H.; Li, Q.; Zhang, T.; Ding, L.; Zhang, L.; Shi, H.; Yanagita, T.; Xue, C.; Chang, Y.; Wang, Y. A comparative study of EPA-enriched ethanolamine plasmalogen and EPA-enriched phosphatidylethanolamine on Aβ42 induced cognitive deficiency in a rat model of Alzheimer’s disease. Food Funct. 2018, 9, 3008–3017. [Google Scholar] [CrossRef]
  155. Ifuku, M.; Katafuchi, T.; Mawatari, S.; Noda, M.; Miake, K.; Sugiyama, M.; Fujino, T. Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J. Neuroinflamm. 2012, 9, 197. [Google Scholar] [CrossRef]
  156. Yamashita, S.; Hashimoto, M.; Haque, A.M.; Nakagawa, K.; Kinoshita, M.; Shido, O.; Miyazawa, T. Oral Administration of Ethanolamine Glycerophospholipid Containing a High Level of Plasmalogen Improves Memory Impairment in Amyloid beta-Infused Rats. Lipids 2017, 52, 575–585. [Google Scholar] [CrossRef]
  157. Yamashita, S.; Kanno, S.; Nakagawa, K.; Kinoshita, M.; Miyazawa, T. Extrinsic plasmalogens suppress neuronal apoptosis in mouse neuroblastoma Neuro-2A cells: Importance of plasmalogen molecular species. RSC Adv. 2015, 5, 61012–61020. [Google Scholar] [CrossRef]
  158. Youssef, M.; Ibrahim, A.; Akashi, K.; Hossain, M.S. PUFA-Plasmalogens Attenuate the LPS-Induced Nitric Oxide Production by Inhibiting the NF-kB, p38 MAPK and JNK Pathways in Microglial Cells. Neuroscience 2019, 397, 18–30. [Google Scholar] [CrossRef] [PubMed]
  159. Onodera, T.; Futai, E.; Kan, E.; Abe, N.; Uchida, T.; Kamio, Y.; Kaneko, J. Phosphatidylethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on γ-secretase activity. J. Biochem. 2014, 157, 301–309. [Google Scholar] [CrossRef] [PubMed]
  160. Miyazawa, T.; Itaya, M.; Burdeos, G.C.; Nakagawa, K.; Miyazawa, T. A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology. Int. J. Nanomed. 2021, 16, 3937–3999. [Google Scholar] [CrossRef]
  161. Hino, K.; Kaneko, S.; Harasawa, T.; Kimura, T.; Takei, S.; Shinohara, M.; Yamazaki, F.; Morita, S.-y.; Sato, S.; Kubo, Y.; et al. Change in Brain Plasmalogen Composition by Exposure to Prenatal Undernutrition Leads to Behavioral Impairment of Rats. J. Neurosci. 2019, 39, 7689–7702. [Google Scholar] [CrossRef]
  162. Miville-Godbout, E.; Bourque, M.; Morissette, M.; Al-Sweidi, S.; Smith, T.; Mochizuki, A.; Senanayake, V.; Jayasinghe, D.; Wang, L.; Goodenowe, D.; et al. Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice. PLoS ONE 2016, 11, e0151020. [Google Scholar] [CrossRef]
  163. Fallatah, W.; Smith, T.; Cui, W.; Jayasinghe, D.; Di Pietro, E.; Ritchie, S.A.; Braverman, N. Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of Rhizomelic chondrodysplasia punctata. Dis. Model. Mech. 2020, 13, dmm042499. [Google Scholar] [CrossRef] [PubMed]
  164. Nadeau, J.; Smith, T.; Lamontagne-Proulx, J.; Bourque, M.; Al Sweidi, S.; Jayasinghe, D.; Ritchie, S.; Di Paolo, T.; Soulet, D. Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor. Brain Res. 2019, 1725, 146460. [Google Scholar] [CrossRef] [PubMed]
  165. Dorninger, F.; Vaz, F.M.; Waterham, H.R.; van Klinken, J.B.; Zeitler, G.; Forss-Petter, S.; Berger, J.; Wiesinger, C. Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters. Brain Res. Bull. 2022, 189, 69–79. [Google Scholar] [CrossRef]
  166. Che, H.; Zhou, M.; Zhang, T.; Zhang, L.; Ding, L.; Yanagita, T.; Xu, J.; Xue, C.; Wang, Y. EPA enriched ethanolamine plasmalogens significantly improve cognition of Alzheimer’s disease mouse model by suppressing β-amyloid generation. J. Funct. Foods 2018, 41, 9–18. [Google Scholar] [CrossRef]
  167. Ding, L.; Zhang, L.; Shi, H.; Xue, C.; Yanagita, T.; Zhang, T.; Wang, Y. EPA-enriched ethanolamine plasmalogen alleviates atherosclerosis via mediating bile acids metabolism. J. Funct. Foods 2020, 66, 103824. [Google Scholar] [CrossRef]
  168. Ding, L.; Zhang, L.-Y.; Shi, H.-H.; Wang, C.-C.; Jiang, X.-M.; Xue, C.-H.; Yanagita, T.; Zhang, T.-T.; Wang, Y.-M. Eicosapentaenoic Acid-Enriched Phosphoethanolamine Plasmalogens Alleviated Atherosclerosis by Remodeling Gut Microbiota to Regulate Bile Acid Metabolism in LDLR–/– Mice. J. Agric. Food Chem. 2020, 68, 5339–5348. [Google Scholar] [CrossRef]
  169. Wang, X.; Chen, Q.; Wang, X.; Cong, P.; Xu, J.; Xue, C. Lipidomics Approach in High-Fat-Diet-Induced Atherosclerosis Dyslipidemia Hamsters: Alleviation Using Ether-Phospholipids in Sea Urchin. J. Agric. Food Chem. 2021, 69, 9167–9177. [Google Scholar] [CrossRef]
  170. Nguma, E.; Tominaga, Y.; Yamashita, S.; Otoki, Y.; Yamamoto, A.; Nakagawa, K.; Miyazawa, T.; Kinoshita, M. Dietary PlsEtn Ameliorates Colon Mucosa Inflammatory Stress and ACF in DMH-Induced Colon Carcinogenesis Mice: Protective Role of Vinyl Ether Linkage. Lipids 2021, 56, 167–180. [Google Scholar] [CrossRef]
  171. Jang, J.E.; Park, H.S.; Yoo, H.J.; Baek, I.J.; Yoon, J.E.; Ko, M.S.; Kim, A.R.; Kim, H.S.; Park, H.S.; Lee, S.E.; et al. Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice. Hepatology 2017, 66, 416–431. [Google Scholar] [CrossRef] [PubMed]
  172. Jacobson, A.; Yang, D.; Vella, M.; Chiu, I.M. The intestinal neuro-immune axis: Crosstalk between neurons, immune cells, and microbes. Mucosal Immunol. 2021, 14, 555–565. [Google Scholar] [CrossRef]
  173. Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. Gastroenterology 2012, 142, 46–54.e42. [Google Scholar] [CrossRef]
  174. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
  175. Jaszewski, R. Aging and cancer of the stomach and colon. Front. Biosci. 1999, 4, 322–328. [Google Scholar] [CrossRef]
  176. Triantafillidis, J.K.; Nasioulas, G.; Kosmidis, P.A. Colorectal cancer and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009, 29, 2727–2737. [Google Scholar]
  177. Lopez, D.H.; Bestard-Escalas, J.; Garate, J.; Maimó-Barceló, A.; Fernández, R.; Reigada, R.; Khorrami, S.; Ginard, D.; Okazaki, T.; Fernández, J.A.; et al. Tissue-selective alteration of ethanolamine plasmalogen metabolism in dedifferentiated colon mucosa. Biochim. Biophys. Acta 2018, 1863, 928–938. [Google Scholar] [CrossRef]
  178. Zhan, Y.; Wang, L.; Liu, J.; Ma, K.; Liu, C.; Zhang, Y.; Zou, W. Choline Plasmalogens Isolated from Swine Liver Inhibit Hepatoma Cell Proliferation Associated with Caveolin-1/Akt Signaling. PLoS ONE 2013, 8, e77387. [Google Scholar] [CrossRef] [PubMed]
  179. Nguma, E.; Yamashita, S.; Han, K.H.; Otoki, Y.; Yamamoto, A.; Nakagawa, K.; Fukushima, M.; Miyazawa, T.; Kinoshita, M. Dietary Ethanolamine Plasmalogen Alleviates DSS-Induced Colitis by Enhancing Colon Mucosa Integrity, Antioxidative Stress, and Anti-inflammatory Responses via Increased Ethanolamine Plasmalogen Molecular Species: Protective Role of Vinyl Ether Linkages. J. Agric. Food Chem. 2021, 69, 13034–13044. [Google Scholar] [CrossRef]
  180. Nguma, E.; Yamashita, S.; Kumagai, K.; Otoki, Y.; Yamamoto, A.; Eitsuka, T.; Nakagawa, K.; Miyazawa, T.; Kinoshita, M. Ethanolamine Plasmalogen Suppresses Apoptosis in Human Intestinal Tract Cells in Vitro by Attenuating Induced Inflammatory Stress. ACS Omega 2021, 6, 3140–3148. [Google Scholar] [CrossRef]
  181. Misawa, N.; Osaki, T.; Takeuchi, S. Membrane protein-based biosensors. J. R. Soc. Interface 2018, 15, 20170952. [Google Scholar] [CrossRef]
  182. Tabata, M.; Miyahara, Y. From new materials to advanced biomedical applications of solid-state biosensor: A review. Sens. Actuators B Chem. 2022, 352, 131033. [Google Scholar] [CrossRef]
  183. Abe, C.; Bhaswant, M.; Miyazawa, T.; Miyazawa, T. The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages. Pharmaceutics 2023, 15, 1024. [Google Scholar] [CrossRef] [PubMed]
  184. Nikoleli, G.-P.; Nikolelis, D.P.; Siontorou, C.G.; Karapetis, S.; Nikolelis, M.-T. Application of Biosensors Based on Lipid Membranes for the Rapid Detection of Toxins. Biosensors 2018, 8, 61. [Google Scholar] [CrossRef] [PubMed]
  185. Naaman, R.; Capua, E.; Bavli, D.; Tkachev, M. Protein Detector Based on Molecular Controlled Semiconductor Resistor. U.S. Patent No. 8,957,460, 17 February 2015. [Google Scholar]
  186. Khashab, N.M.; Caruso, F. The Future of Healthcare Materials. Chem. Mater. 2023, 35, 364–365. [Google Scholar] [CrossRef]
  187. Thompson, D.H.; Gerasimov, O.V.; Wheeler, J.J.; Rui, Y.; Anderson, V.C. Triggerable plasmalogen liposomes: Improvement of system efficiency. Biochim. Biophys. Acta 1996, 1279, 25–34. [Google Scholar] [CrossRef]
  188. Rani, V.; Venkatesan, J.; Prabhu, A. Liposomes- A promising strategy for drug delivery in anticancer applications. J. Drug Deliv. Sci. Technol. 2022, 76, 103739. [Google Scholar] [CrossRef]
  189. Lajunen, T.; Nurmi, R.; Kontturi, L.; Viitala, L.; Yliperttula, M.; Murtomäki, L.; Urtti, A. Light activated liposomes: Functionality and prospects in ocular drug delivery. J. Control. Release 2016, 244, 157–166. [Google Scholar] [CrossRef]
  190. Zhang, Y.; Li, Y.; Ma, J.; Wang, X.; Yuan, Z.; Wang, W. Convenient preparation of charge-adaptive chitosan nanomedicines for extended blood circulation and accelerated endosomal escape. Nano Res. 2018, 11, 4278–4292. [Google Scholar] [CrossRef]
  191. Rietwyk, S.; Peer, D. Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 2017, 11, 7572–7586. [Google Scholar] [CrossRef]
  192. Fay, F.; Quinn, D.J.; Gilmore, B.F.; McCarron, P.A.; Scott, C.J. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 2010, 31, 4214–4222. [Google Scholar] [CrossRef] [PubMed]
  193. Ma, D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 2014, 6, 6415–6425. [Google Scholar] [CrossRef]
  194. Jayaraman, M.; Ansell, S.M.; Mui, B.L.; Tam, Y.K.; Chen, J.; Du, X.; Butler, D.; Eltepu, L.; Matsuda, S.; Narayanannair, J.K.; et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 2012, 51, 8529–8533. [Google Scholar] [CrossRef] [PubMed]
Molecules 28 06328 g001
Figure 1. Alteration of lipid levels in blood of patients with AD [97]. Marks indicate significant differences between blood levels of patients with AD and their spouses (healthy subjects): *** p < 0.001, ** p < 0.01, * p < 0.05. AD, Alzheimer’s disease; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EtnGpl, ethanolamine glycerophospholipid; OA, oleic acid; PCOOH, phosphatidylcholine hydroperoxide; PLOOH, phospholipid hydroperoxide; PlsEtn, ethanolamine plasmalogen.
Figure 1. Alteration of lipid levels in blood of patients with AD [97]. Marks indicate significant differences between blood levels of patients with AD and their spouses (healthy subjects): *** p < 0.001, ** p < 0.01, * p < 0.05. AD, Alzheimer’s disease; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EtnGpl, ethanolamine glycerophospholipid; OA, oleic acid; PCOOH, phosphatidylcholine hydroperoxide; PLOOH, phospholipid hydroperoxide; PlsEtn, ethanolamine plasmalogen.
Molecules 28 06328 g001
Molecules 28 06328 g002
Figure 2. Effects of lipids on Aβ fibril formation [97]. (a) Aβ aggregation assay. (b) Aβ destabilization assay. Their values are expressed as a percentage of control aggregation, which was observed in the absence of 20 μM lipids. Aβ, amyloid β; ARA, arachidonic acid; DHA, docosahexaenoic acid; OA, oleic acid; PlsEtn, ethanolamine plasmalogen; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine.
Figure 2. Effects of lipids on Aβ fibril formation [97]. (a) Aβ aggregation assay. (b) Aβ destabilization assay. Their values are expressed as a percentage of control aggregation, which was observed in the absence of 20 μM lipids. Aβ, amyloid β; ARA, arachidonic acid; DHA, docosahexaenoic acid; OA, oleic acid; PlsEtn, ethanolamine plasmalogen; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine.
Molecules 28 06328 g002
Molecules 28 06328 g003
Figure 3. PlsEtn distribution in marine invertebrates on phylogenetic tree [7]. Marks indicate ratio of PlsEtn to ethanolamine glycerophospholipid: ☆ > 90 mol%, ○ 80–90 mol%, △ 50–80 mol%, × < 50 mol%. PlsEtn, ethanolamine plasmalogen.
Figure 3. PlsEtn distribution in marine invertebrates on phylogenetic tree [7]. Marks indicate ratio of PlsEtn to ethanolamine glycerophospholipid: ☆ > 90 mol%, ○ 80–90 mol%, △ 50–80 mol%, × < 50 mol%. PlsEtn, ethanolamine plasmalogen.
Molecules 28 06328 g003
Molecules 28 06328 g004
Figure 4. Composition of PlsEtn species in foodstuffs [8]. Numbers on bars indicate total PlsEtn content. M, muscle; Ma, mantle; LM, leg muscle; PlsEtn, ethanolamine plasmalogen; V, viscera.
Figure 4. Composition of PlsEtn species in foodstuffs [8]. Numbers on bars indicate total PlsEtn content. M, muscle; Ma, mantle; LM, leg muscle; PlsEtn, ethanolamine plasmalogen; V, viscera.
Molecules 28 06328 g004
Molecules 28 06328 g005
Figure 5. Application of plasmalogen as a healthcare material in (A) biosensors, (B) light-activated liposomes, and (C) nanoparticles with endosomal escape capabilities. (A) was modified with permission from [184] under the Creative Commons CC BY 4.0 license, https://creativecommons.org/licenses/by/4.0/ (accessed on 25 June 2023).
Figure 5. Application of plasmalogen as a healthcare material in (A) biosensors, (B) light-activated liposomes, and (C) nanoparticles with endosomal escape capabilities. (A) was modified with permission from [184] under the Creative Commons CC BY 4.0 license, https://creativecommons.org/licenses/by/4.0/ (accessed on 25 June 2023).
Molecules 28 06328 g005
Table 1. Composition of plasmalogen in different mammalian organs and tissues.
Table 1. Composition of plasmalogen in different mammalian organs and tissues.
SpeciesOrgans and TissuesPlsEtn
(% EtnGpl)		PlsEtn
(% Total PL)		PlsCho
(% ChoGpl)		PlsCho
(% Total PL)		Plasmalogen
(% Total PL)		Plasmalogen
(% Wet Weight)		Refs.
Human
Whole brain5820, 2210.8, 0.922 [17,18]
Brain prefrontal cortex49 0.7 [19]
Brain temporal cortex46 0.5
Brain gray matter49190.1 190.4, 0.7[20,21]
Brain gray matter—frontal cortex57 200.7[10,22]
Brain gray matter—parietal cortex58 190.7
Brain gray matter—temporal cortex56
Brain gray matter—cerebellum63
Brain white matter83, 86332.6, 0.40.1371.1, 1.8[19,20,21]
Brain white matter—frontal cortex84 292[10,22]
Brain white matter—parietal cortex81 362.7
Brain white matter—temporal cortex83
Brain white matter—cerebellum78
Myelin91360.50.1437.0[20]
Heart53, 5117, 14, 1526, 3614, 11, 1532, 29 [17,18,23]
Skeletal muscle48, 6314, 1519, 166.5, 9.7 0.2[17,18,22,23]
Cultured artery endothelial cells48131.90.9 [24]
Cultured vein endothelial cells348.70.20.1
Kidney461454.7 [17,18]
Liver84.733.4
Colon361193.919, 150.1, 0.1[22,25]
Lens7014 [26]
Neutrophils68 3.6 [27]
Eosinophils72 4 [28]
Red blood cells58, 48, 4617,14, 982.820, 14, 9 [29,30,31]
Plasma532.55.55.27.7 [32]
Serum 5.9 4.510 [33]
HDL556.4, 54.74.5, 411, 10 [32,34]
LDL605.9, 44.44.2, 410, 10
Platelet54 0.8 [35]
Cultured macrophage62 8.8 [36]
Spermatozoa 9 312 [37]
Rat
Whole brain66 1.7 1[19,22]
Cortex 22 [38]
Cerebellum 26
Hippocampus 23
Brainstem 32
Midbrain 24
Brain synaptic vesicles 16 [39]
Heart289.85.72.4120.2[22,40]
Cultured heart sacrolemma43 19 [41]
Lung42 1.6 160.3[22,42]
Kidney20 2.3 120.3
Liver3.3 0.4 3.40.07
Red blood cells65160.90.516 [13]
Plasma51, 360.40.50.40.8 [13,43]
HDL46 2.4 [43]
LDL32 1.9
VLDL14 1.6
Mature spermatozoa42 52 38 [44]
Mouse
Whole brain47 1.2 [19]
Cortex46 [10,22]
Cerebellum53
Heart248.2623139 [45]
Dog
Heart sarcolemma7316573753 [46]
Rabbit
Whole brain 261.3[22]
Heart 320.6
Lung 140.3
Kidney 140.3
Liver 20.06
Macrophage61136215 [47]
Guinea pig
Whole brain 0.9[21]
The composition of this table was primarily created by referring to [14,15] with their permission. For references [20,22], the values displayed in the table were converted from the data in the literature. Average molecular weight of glycerophospholipids used was 775. ChoGpl, choline glycerophospholipid; EtnGpl, ethanolamine glycerophospholipid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PL, phospholipid; PlsCho, choline plasmalogen; PlsEtn, ethanolamine plasmalogen; VLDL, very-low-density lipoprotein.
Table 2. Predominant plasmalogen species found in different mammalian organs and tissues.
Table 2. Predominant plasmalogen species found in different mammalian organs and tissues.
SpeciesOrgans and TissuesPredominant Plasmalogen SpeciesRefs.
Human
Brain gray matter—frontal cortex16:0/18:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:0/22:6-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn[10]
Brain gray matter—parietal cortex16:0/18:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:0/22:6-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Brain gray matter—temporal cortex16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 16:0/22:6-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:0/22:6-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Brain gray matter—cerebellum16:0/18:1-PlsEtn, 16:0/20:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 16:0/22:6-PlsEtn, 18:0/18:1-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:0/22:6-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Brain white matter—frontal cortex16:0/18:1-PlsEtn, 16:0/20:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 18:0/18:1-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:1-PlsEtn,
18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Brain white matter—parietal cortex16:0/18:1-PlsEtn, 16:0/20:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 18:0/18:1-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:1-PlsEtn,
18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Brain white matter—temporal cortex16:0/18:1-PlsEtn, 16:0/20:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 18:0/18:1-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:1-PlsEtn,
18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Brain white matter—cerebellum16:0/18:1-PlsEtn, 16:0/20:1-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 18:0/18:1-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:4-PlsEtn, 18:0/22:5-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:1-PlsEtn,
18:1/20:4-PlsEtn, 18:1/22:4-PlsEtn
Cultured artery endothelial cells16:0/20:4-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 16:0/22:6-PlsEtn, 18:0/20:4-PlsEtn, 18:1/20:4-PlsEtn[24]
Cultured vein endothelial cells16:0/20:4-PlsEtn, 16:0/22:4-PlsEtn, 16:0/22:5-PlsEtn, 16:0/22:6-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:5-PlsEtn, 18:0/22:6-PlsEtn
Neutrophils16:0/18:1-PlsEtn, 16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 18:0/18:1-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:1/18:1-PlsEtn, 18:1/18:2-PlsEtn, 18:1/20:4-PlsEtn, 20:0/18:1-PlsEtn, 20:0/18:2-PlsEtn, 20:0/20:4-PlsEtn, 22:0/18:1-PlsEtn, 22:1/18:1-PlsEtn, 22:1/18:2-PlsEtn, 22:1/20:4-PlsEtn, 24:1/18:1-PlsEtn, 24:1/18:2-PlsEtn, 24:1/20:4-PlsEtn[48]
Lymphocytes16:0/18:1-PlsEtn, 16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 16:0/22:6-PlsEtn[49]
Serum16:0/18:1-PlsEtn, 16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 16:0/22:6-PlsEtn, 18:0/18:1-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:6-PlsEtn[50]
HDL16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 16:0/22:6-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:6-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:6-PlsEtn
16:0/18:1-PlsCho, 16:0/18:2-PlsCho, 16:0/20:4-PlsCho, 16:0/22:6-PlsCho, 18:0/18:2-PlsCho, 18:0/20:4-PlsCho, 18:1/20:4-PlsCho		[34]
LDL16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 16:0/22:6-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:6-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:6-PlsEtn
16:0/18:1-PlsCho, 16:0/18:2-PlsCho, 16:0/20:4-PlsCho, 16:0/22:6-PlsCho, 18:0/18:2-PlsCho, 18:0/20:4-PlsCho
VLDL16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 16:0/22:6-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:6-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:6-PlsEtn
16:0/18:1-PlsCho, 16:0/18:2-PlsCho, 16:0/20:4-PlsCho, 16:0/22:6-PlsCho, 18:0/18:2-PlsCho, 18:0/20:4-PlsCho, 18:1/20:4-PlsCho
Platelet16:0/18:2-PlsEtn, 16:0/20:4-PlsEtn, 18:0/20:4-PlsEtn
16:0/20:4-PlsCho, 18:0/20:4-PlsCho, 18:1/20:4-PlsCho		[35]
Rat
Cardiac sarcolemma16:0/18:0-PlsEtn, 16:0/18:3-PlsEtn, 18:0/18:0-PlsEtn, 18:0/22:4-PlsEtn, 18:1/18:1-PlsEtn, 18:2/16:0-PlsEtn, 18:2/18:0-PlsEtn
16:0/18:0-PlsCho, 16:0/18:2-PlsCho, 16:0/18:3-PlsCho, 18:0/18:0-PlsCho, 18:0/20:4-PlsCho, 18:0/22:6-PlsCho, 18:1/22:6-PlsCho		[51]
Mouse
Cerebral cortex16:0/18:1-PlsEtn, 16:0/20:1-PlsEtn, 16:0/22:6-PlsEtn, 18:0/18:1-PlsEtn, 18:0/20:4-PlsEtn, 18:0/22:6-PlsEtn, 18:1/16:0-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:4-PlsEtn, 18:1/22:6-PlsEtn[52]
Hippocampus18:1/20:3-PlsEtn, 18:1/20:4-PlsEtn, 18:0/22:5-PlsEtn, 18:1/22:4-PlsEtn
16:0/18:1-PlsCho, 16:0/20:5-PlsCho, 16:0/22:5-PlsCho, 18:0/16:0-PlsCho		[53]
Macrophage cell line RAW264.716:0/18:1-PlsEtn, 16:0/20:3-PlsEtn, 16:0/20:4-PlsEtn, 18:0/18:1-PlsEtn, 18:0/20:3-PlsEtn, 18:0/20:4-PlsEtn, 18:1/16:0-PlsEtn, 18:1/18:1-PlsEtn, 18:1/20:3-PlsEtn, 18:1/20:4-PlsEtn[54]
Rabbit
Proximal tubules16:0/18:1-PlsEtn, 16:0/20:4-PlsEtn, 18:0/18:2-PlsEtn, 18:0/20:4-PlsEtn, 18:1/18:2-PlsEtn, 18:1/20:4-PlsEtn[55]
Dog
Heart sarcolemma16:0/20:4-PlsEtn, 18:0/20:4-PlsEtn, 18:1/20:4-PlsEtn
16:0/18:1-PlsCho, 16:0/18:2-PlsCho, 16:0/20:4-PlsCho, 16:0/18:2-PlsCho, 18:1/18:1-PlsCho		[46]
Plasmalogen species greater than 5% of total PlsEtn or PlsCho are listed in the table. Only for the data from [48,49,50], all identified plasmalogen species were listed. The fatty chain combination is written as follows: 18:0/22:6-PlsEtn means 1-(1Z-octadecenyl)-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine. HDL, high-density lipoprotein; LDL, low-density lipoprotein; PlsCho, choline plasmalogen; PlsEtn, ethanolamine plasmalogen; VLDL, very-low-density lipoprotein.
Table 3. Effects of plasmalogen administration on age-associated diseases, including cognitive impairments, in clinical studies.
Table 3. Effects of plasmalogen administration on age-associated diseases, including cognitive impairments, in clinical studies.
Resource and DoseSubjectEffectsRefs.
Scallop
Plasmalogen composition: unclear
1.0 mg/day for 24 weeks		Mild AD and MCI
Placebo: n = 140, age 76.5, MMSE 24.2
1.0 mg: n = 145, age 76.4, MMSE 24.0		Not affected in whole
In mild AD (MMSE 20–23)
Female: WMS-R improvement compared with the placebo
Younger than 78: WMS-R improvement compared with the placebo		[11]
Scallop
Plasmalogen composition: unclear
1.0 mg/day for 24 weeks		MCI
Placebo: n = 88, age 75.9, MMSE 25.6
1.0 mg: n = 90, age 75.8, MMSE 25.6		Improvement in total MMSE compared with before the intake
Improvement in domain “orientation to place” compared with the placebo and before the intake
Maintenance of domain “orientation to time” compared with before the intake		[143]
Scallop
Plasmalogen composition: unclear
0.5 or 1.0 mg/day for 12 weeks		Moderate-to-severe AD
0.5 mg: n = 68, age 78.5, MMSE 13.0
1.0 mg: n = 74, age 76.6, MMSE 13.4		Improvement in total MMSE compared with before the intake
Increase in plasma and RBC levels of PlsEtn compared with before the intake
Increase in plasma PlsEtn levels in the 0.5 mg group compared with the 1.0 mg group
Correlation between changes in MMSE and RBC PlsEtn		[144]
Scallop
Ether lipid composition: 52% PlsEtn, 2% PlsCho, 4% PakEtn, 42% PakCho
1.0 mg/day for 24 weeks		PD
PD: n = 10, age 67.8, MMSE 28.6		Improvement in total PDQ-39 compared with immediately before trial
Deterioration of total PDQ-39 at 4 weeks later of the final administration
Increase in plasma and RBC levels of PlsEtn compared with levels immediately before trial
Decrease in RBC PlsEtn levels after 4 weeks without administration 		[142]
Ascidian
Plasmalogen composition: unclear
1.0 mg/day for 12 weeks		Healthy subjects with mild forgetfulness
Placebo: n = 24, age 46.4, MMSE 29.0
1.0 mg: n = 25, age 45.6, MMSE 28.5		Improvement in Cognitrax domain “composite memory” at 8 and 12 weeks compared with the placebo[145]
Ascidian
Plasmalogen composition: 100% PlsEtn, trace PlsCho
0.5 or 1.0 mg/day for 12 weeks		MCI
Placebo: n = 44, age 51.4, MMSE 25.3
0.5 mg: n = 45, age 51.5, MMSE 25.4
1.0 mg: n = 49, age 52.7, MMSE 25.7		Improvement in CogEvo domain “working memory performance” in the 1.0 mg group compared with the placebo
In subjects older than 49
Improvement in total MMSE and “working memory performance” in the 1.0 mg group compared with the placebo		[12]
Chicken breast
Plasmalogen composition: unclear
1.0, 10, or 100 mg/day for 12 weeks		Healthy subjects with mild forgetfulness
Placebo: n = 17, age 58.7
1.0 mg: n = 15, age 57.2
10 mg: n = 16, age 59.9
100 mg: n = 15, age 59.0		Improvement in total RBANS in the 1.0 and 100 mg groups compared with before the intake
Improvement in RBANS domain “attention” in all the groups, including the placebo, compared with before the intake
Improvement in some Cognitrax domains in the plasmalogen groups compared with before the intake		[146]
Chicken breast
Plasmalogen composition: unclear
0.5 or 1.0 mg/day for 12 weeks		Healthy subjects with mild forgetfulness
age 50 to 79, MSSE > 26
Placebo: n = 24
0.5 mg: n = 25
1.0 mg: n = 25		Improvement in some CogEvo domains in all the groups, including the placebo, compared with before the intake
In subjects older than 59
Improvement in some CogEvo domains in the 1.0 mg group compared with before the intake
Improvement in CogEvo domain “verbal memory” in the 1.0 mg group compared with the placebo
Improvement in CogEvo domain “psychomotor speed” in the 0.5 mg group compared with the placebo		[147]
AD, Alzheimer’s disease; MCI, mild cognitive impairment; MMSE, mini mental state examination; PakCho, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine; PakEtn, 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine; PD, Parkinson’s disease; PDQ-39, Parkinson’s disease questionnaire-39; PlsCho, choline plasmalogen; PlsEtn, ethanolamine plasmalogen; RBANS, repeatable battery for the assessment of neuropsychological status; RBC, red blood cell; WMS-R, Wechsler memory scale—revised.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yamashita, S.; Miyazawa, T.; Higuchi, O.; Kinoshita, M.; Miyazawa, T. Marine Plasmalogens: A Gift from the Sea with Benefits for Age-Associated Diseases. Molecules 2023, 28, 6328. https://doi.org/10.3390/molecules28176328

AMA Style

Yamashita S, Miyazawa T, Higuchi O, Kinoshita M, Miyazawa T. Marine Plasmalogens: A Gift from the Sea with Benefits for Age-Associated Diseases. Molecules. 2023; 28(17):6328. https://doi.org/10.3390/molecules28176328

Chicago/Turabian Style

Yamashita, Shinji, Taiki Miyazawa, Ohki Higuchi, Mikio Kinoshita, and Teruo Miyazawa. 2023. "Marine Plasmalogens: A Gift from the Sea with Benefits for Age-Associated Diseases" Molecules 28, no. 17: 6328. https://doi.org/10.3390/molecules28176328

APA Style

Yamashita, S., Miyazawa, T., Higuchi, O., Kinoshita, M., & Miyazawa, T. (2023). Marine Plasmalogens: A Gift from the Sea with Benefits for Age-Associated Diseases. Molecules, 28(17), 6328. https://doi.org/10.3390/molecules28176328

Article Metrics

Back to TopTop